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SUMMARY 
Highly functional in vitro cultured cells are of great usefulness in various applications 
such as cell-based testing, constructing large tissues and pathological research. The 
key to culturing functional cells in vitro is to recapitulate an in vivo-like cellular 
microenvironment which allows extensive mechanical support as well as cell-cell, 
cell-matrix and cell-soluble factor interactions. The development of microfluidic cell 
culture devices has made possible the controlling cellular microenvironments, 
phenotypes and behaviors under novel experimentations. Although they are believed 
to be advantageous over other systems in terms of a more controllable 
microenvironment, few attempts to engineer a soluble microenvironment for 
extensive cell-soluble factor interactions within these microfluidic systems are 
reported. Hence, there is a great need to develop an in vitro model with 
well-controlled soluble microenvironment to primarily supplement in vivo animal 
models, thus reducing the cost and ethical issues surrounding animal experimentation.  
 
This thesis demonstrates the strategy of engineering soluble microenvironments in 
microfluidic cell culture systems for various cell types, which significantly enhanced 
biological functions of either primary cells or cell lines. To engineer the soluble 
microenvironment, growth factors were loaded to gelatin microspheres (GMs) and the 
growth factor-releasing GMs were immobilized together with cells in the microfluidic 
cell culture system to enhance cellular functions. Characterizations have shown that 
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the growth factor-releasing GMs were able to give rise to an isolated and stable 
soluble microenvironment even under constant fluid perfusion.  
 
When multiple cell types were cultured inside one system simultaneously, their 
individual soluble microenvironment can still be established without interference with 
each other. Such an in vitro cell culture model could aid or even, in a later stage, 
replace animal models for studying the systemic effect of a chemical in 
pharmaceutical or food industry (i.e. the pharmacokinetic and pharmacodynamic 
characterizations of newly synthesized drugs in the screening process).  
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CHAPTER 1 Introduction 
Cells exist within a complex microenvironment consisting of an insoluble 
extracellular matrix (ECM) which contains proteins for cell adhesion and cell-matrix 
interactions, neighboring cells that allow for extensive cell-cell interactions, and 
soluble factors for cell-soluble factor interactions.1 In cell culture, the recapitulated 
microenvironment experienced by the cells can reflect the physiological relevance to 
in vivo environment and affect cellular behaviors.2 This claim is proved by various 
studies such as, basic fibroblast growth factor (bFGF) was found to be central to the 
maintenance of neural stem cells in mouse brain3 and can enhance neural progenitor 
proliferation in vitro;4 elevated levels of ECM fibronectin was discovered to 
contribute to the formation of a pre-metastatic niche;5 and Chen et al. demonstrated 
that creating cellular microenvironments can improve cell-based drug testing.2  
 
Currently we have plenty of powerful tools in hand to create controllable 
microenvironments that mimic in vivo situations for experimental and therapeutic 
applications. These tools include chemically modified surfaces for cell cultures;6-8 
scaffolds with defined mechanical properties for tethering9, 10 or encapsulating11 
growth factors; co-culture techniques and various microscale cell culture systems,12-14 
etc. Among them, microscale cell culture has been advantageous in enabling novel 
experiments that incorporates micropatterning technologies to precisely control 
cell-cell and cell-matrix interactions.1, 13 Likewise, microfluidic cell culture systems 
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allow novel experiments for controlling the microenvironment, which affects cellular 
phenotypes.15 
 
Microfluidic cell culture systems are believed to be able to create a defined, constant 
microenvironment by continuously controlling the supply and removal of soluble 
factors.15 Recently, many three-dimensional (3D) microfluidic devices have been 
developed for enabling cell-cell and cell-matrix interactions during cell culture.16, 17 
However, few attempts to engineer a soluble microenvironment for extensive 
cell-soluble factor interactions within the microfluidic devices are reported. Hence, 
there is a great need to develop an in vitro model with well-controlled soluble 
microenvironment to primarily enhance cellular functions in vitro and thus 
supplementing in vivo animal models such as mice, rat and rabbits, reducing the cost 
and ethical issues surrounding animal experimentation.18  
 
Growth factors, cytokines, and chemokines (or known as soluble factors) are the main 
constituents in the soluble microenvironment.19 However, these molecules have very 
short half-life (several to 20 minutes) in aqueous solutions,20 which impedes their 
roles in the functional enhancement of cells. The activity of the soluble factors can be 
preserved from inactivation by encapsulation in controlled-release carriers for up to 
several days.21 The material of the controlled-release carriers are normally made from 
biocompatible materials which does not cause any side effect to the cells.22 We 
hypothesized that stable cell-soluble factor interactions can be established for 
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functional enhancement of cells, with laminar flow within microfluidic devices and 
continuous release of soluble factors from their carriers. Thus, to test the hypothesis, 
we report in this thesis a strategy to engineer a soluble microenvironment by 
controlled-releasing of a growth factor, transforming growth factor-beta 1 (TGF-β1), 
from GMs to 3D microfluidic cell culture systems (3D-μFCCS). Characterizations 
have confirmed that a stable soluble microenvironment can be established even under 
perfusion within the 3D-μFCCS. Two cell-based applications of such a soluble 
microenvironment are also demonstrated in this thesis. 
 
A literature review is presented in the next chapter to provide a background for these 
studies, detailing the importance of constructing a microenvironment and the various 
strategies employed. The strategies of microscale cell culture are also introduced, with 
emphasis on microfluidics. The chapter ends with the review of controlled-release 
technique and its usefulness in constructing a soluble microenvironment, leading to 
the three specific aims of this thesis, as presented in Chapter 3. Chapter 4 describes 
the characterization of the soluble microenvironment on chip. In Chapters 5 and 6, 
two different applications of the engineered soluble microenvironment are presented 
respectively. Chapter 7 concludes the major findings in the thesis as well as their 
implications. The thesis ends with recommendations for future studies as presented in 
Chapter 8. 
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CHAPTER 2 Background and Significance 
This chapter presents background information that defines the rationale for the study. 
Section 2.1 elucidates the biological significance of constructing a microenvironment 
for in vitro cell cultures, and the various strategies for creating a microenvironment. 
Section 2.2 focuses on novel microscale cell cultures, which bridges microfabrication 
technology to general cell cultures for various biological applications. This new 
technique of cell culture is considered to be able to provide the cells with a 
controllable microenvironment. Section 2.3 reviews the background information of 
controlled release technology and how it has been employed to engineer a 
microenvironment. Section 2.4 concludes with the limitations of current cell culture 
strategies in terms of recapitulating a microenvironment and hence the rationale for 
the thesis research. 
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2.1 Constructing a microenvironment for in vitro cell cultures 
2.1.1 Importance of constructing a microenvironment in vitro 
Cell culture is fundamental to research on cell biology and biotechnology.23, 24 
Majority of our current understandings of the cellular structures and functions are 
based on cell cultures.25, 26 The conditions and microenvironments in which the cells 
are cultured greatly influence their behaviours.27 In the cellular microenvironment, 
cells form strong interactions with their neighboring cells19 and are primarily 
protected by the ECM (Fig. 1), which is constituted of insoluble proteins (e.g. 
collagen, fibronectin, laminin, etc.)28 and provides mechanical support and stimuli to 
the cells.27, 29 In the microenvironment, different kinds of soluble factors are presented 
in the cell vicinity within a gradient, which is the major source of chemical signals to 
the cells.30, 31 
Soluble factors
Mechanical load 
Extracellular matrix  
Figure 1: schem e 
a and diseases are often closely related to changes in the cell-ECM interactions 
as a result of structure and property alterations of the ECM (Fig. 2).32 For instance in 
atic of the cellular microenvironment. ECM, soluble factor and som






cancer, it is always typical to find abnormal ECM accumulation, which leads to 
increased tissue stiffness and the formation of a hypoxic region.33, 34 Therefore, the 
response of the cells to the external stimuli is changed35 and abnormal gene 
expression can be triggered.  
 
 
Figure 2: the cellular microenvironment varies with tissue injury. (a) In a normal ECM, cells 
are anchored to it through multiple receptor-ligand bonds. (b) Tissue injury, which can 
initially reduce the stiffness of the ECM and the number of ligands, can destabilize 
receptor-ligand bonds, leading also to a decrease in cellular contractility. (c) Conversely, 
pathological processes such as tumor formation may lead to enhanced expression of adhesion 
receptors, an accumulation of ECM and other changes in the microenvironment (for example, 
hypoxia).  Images are reproduced with permission from publisher. 32
 
Cells behave very differently in a 3D microenvironment where extensive cell-cell 
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interactions can be easily established as compared to 2D monolayers where cell-cell 
interactions are very limited. For example, a 3D environment was able to promote the 
epithelial polarity and differentiation of breast epithelial cells, which is not observed 
when the cells are cultured in 2D.36 When cultured in 3D microenvironments, primary 
hepatocytes are able to exhibit higher levels of liver-specific functions, such as 
albumin secretion, urea synthesis and enzymatic activities, whereas they rapidly lose 
these functions under 2D culture conditions.37 Cancer cells transform from a 
mesenchymal to an amoeboid motility pattern when cultured in 3D, which is also not 
observed in 2D.38 
 
Cells will exhibit different phenotypes when they are presented in a soluble 
microenvironment with different growth factors, chemokines, and cytokines, etc. For 
example, bone marrow stem cells (BMSCs) possess the potency of differentiating into 
osteoblasts, adipocytes or chondrocytes, depending on the differentiation supplements 
in culture medium.39, 40 Growth factors such as TGF-β1 can trigger the 
epithelial-to-mesenchymal transition of human alveolar epithelial cells.41 
 
Currently, for cell-based applications such as drug testing, the bottleneck is not the 
synthesis of new chemical compound any more, but rather the validation process 
which requires highly functional cells that are close to in vivo situations.2, 42 Therefore, 
creating a controllable microenvironment for in vitro cultured cells is critical in their 
functional enhancement and thus the applications. 
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2.1.2 Strategies of constructing a microenvironment in vitro 
In order to create more in vivo-like microenvironments for cell culture, many 
engineering methods are employed and both natural and synthetic biomaterials are 
chosen for fabricating various systems. This section will focus on reviewing different 
systems as well as materials for engineering a microenvironment in vitro. 
 
a) microencapsulation of cells for in vitro culture 
Microcapsule is so far still the most preferable cell transplantation system.43 The 
concept of this cell encapsulation technique consists of encapsulating the biologically 
active material (e.g. cells) within a semi-permeable membrane that is designed to 
prevent immune rejection. This membrane regulates the cell-soluble factor 
interactions in the cellular microenvironment by controlling the diffusion of nutrients 
and waste. Meanwhile, it prevents immune cells and antibodies, thus reducing craft 
rejections (Fig. 3). 
 
The cell encapsulation techniques can vary, depending on various tissue engineering 
or therapeutic applications.37, 43 The common strategies for cell encapsulation are via 
interfacial precipitation, ionic gelation or complex coacervation.44 Sodium alginate 
and poly-L-lysine have been widely used to encapsulate various cell types.45 Also, 
agarose microspheres,46 cross-linked chitosan membrane,47 ceramic-based 
membrane,44 and other different compositions of poly-acrylic acid based methods 
have been developed as the materials to encapsulate primary cells or cell lines for 
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tissue engineering or other therapeutic applications.48  
 
A stable semi-permeable membrane with good diffusion properties can facilitate the 
long-term functional maintenance of the cells, thereby allowing the treatment of 
chronic diseases. Primary rat hepatocytes can be encapsulated in a layer of complex 
coacervated collagen, which provides enough mechanical support to the cells in the 
cellular microenvironment and could shield shear stress if there is perfusion-based 
culture.43 
 
Figure 3: schematic representation of the microencapsulation technique. The capsule 
membrane allows the bi-directional diffusion of nutrients, oxygen and waste, and the 
secretion of the therapeutic product, but prevents immune cells and antibodies, which might 
destroy the enclosed cells, from entering the capsule.43
 
b) Encapsulation of cells in scaffolds and hydrogels 
Scaffolds have high affinity to water but cannot be dissolved in water due to their 
chemically or physically cross-linked network.49, 50 Water can penetrate the polymer 
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chains, causing swelling and thus the formation of a hydrogel, which is normally the 
material of a scaffold. Scaffolds with high water content mimics the natural ECM, 
making them suitable for a wide range of biological applications.49 Scaffolds are 
fabricated by gas foaming, electrospinning or solvent casting processes, and must 
allow for cell attachment, cell migration and tissue formation.51 The materials of 
scaffolds, or in other words, hydrogels, can be derived from natural materials such as 
hyaluronic acid (HA), collagen, fibrin, alginate and chitin.52 They are biocompatible 
and not toxicic to cells. Natural hydrogels and scaffolds intrinsically contain a variety 
of encapsulated growth factors. Therefore, they can serve as valuable tools to study 
the interplay between the microenvironments and consequent cellular responses (Fig. 
4). It has been discovered that vascular endothelial cells cultured in Matrigel can form 
capillaries with a central lumen.53 However, natural systems complicate the process of 
identifying the role of individual factors in tissue formation. There is also a great 
diversity of synthetic systems, including poly(ethylene glycol) (PEG), 
poly(hydroxymethyl methacrylate) (PHEMA) and poly(vinyl alcohol) (PVA),49 with 
PEG being the most common material. Synthetic scaffolds and hydrogels are easier to 
be manipulated in terms of the combinations of defined components. Growth factors, 
as well as other soluble factors, can be incorporated into the systems as a part of the 
microenvironment. They can be controlled-released from the constructed scaffolds,54 
or tethered to the surface.55 To encapsulate cells in 3D, they are usually suspended in 
liquid hydrogels, followed by external stimuli such as changes in physical or chemical 
conditions for gelation to occur.56 The hydrogel can then surround the cells in a 3D 
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fashion, enabling the delivery of soluble signals to cells in all directions. 
 
Scaffolds and hydrogels have been used extensively in engineering 3D in vitro cell 
culture systems. For example, breast epithelial cells encapsulated and cultured within 
3D hydrogel formed acinus structures, resembling the morphology found in vivo.57 
Fibroblasts in 3D collagen gels have a different shape and a different distribution of 
transmembrane adhesion proteins compared with those within 2D monolayers.58 
 
The materials of scaffolds and hydrogels are degradable, thus allowing cellular 
remodeling.59-61 However, scaffolds and hydrogels pose mass transport problems 
because they are polymers with high molecular weights.62 Moreover, the growth 
factors can only diffuse out through the pores in scaffolds and hydrogels, which is an 
uncontrollable process. 
 
A B C 
 
Figure 4: different types of scaffolds.  (A) synthetic scaffold made by a layer-by-layer 
technique (B) assembly of microscopic Lego-like building blocks into a scaffold (C) a PCL 
scaffold with surface coating. Images are reproduced with permission from publisher.  
52
 
c) Cell patterning technique 
Cell patterning is the process of engineering the material surface properties to 
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precisely control the architecture of multiple cells in culture.31, 63, 64 Cells on patterned 
surfaces can exhibit extensive cell-cell and cell-matrix interactions in the cellular 
microenvironment.31 In many primary hepatocytes-based applications such as drug 
testing, hepatocytes were cultured on modified substrate surfaces to achieve optimal 
cell attachment and functional maintenance.13, 65, 66 Bone marrow stem cells patterned 
on different substrates can differentiate down into different lineages.67 The surface of 
the substrates can simply be coated with natural ECM proteins such as collagen, 
laminin and fibronectin, or can be conjugated with peptides such as Arg-Gly-Asp 
(RGD)68 and Tyr-Ile-Gly-Ser-Arg (YIGSR) (Fig. 5) to guide cell-matrix 
interactions.69 Also, the materials of the substrates vary from glass, plastic, e.g. 




Figure 5: substrates with different patterning. (A) surface coating with proteins (B) surface 
conjugation with peptides 
 
The traditional way for obtaining better defined surfaces is by precoating the surfaces 
with a purified ECM protein, followed by blocking remaining cell adsorption sites on 
the surfaces with a nonadhesive protein such as albumin.31 However, these 
nonadhesive proteins are prone to degradation.31 Thus, a more stable blocking agent 
other than nonadhesive proteins is in need. A more flexible systems to modify 
surfaces for cell adhesion is the alkanethiol self-assembled monolayers (SAMs).73 
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When an alkanethiols solution is coated onto a surface, they organize spontaneously 
into a highly organized molecular coating. The chemistry of the surface is defined by 
the terminal functional groups. Alkanethiols with different terminal functionalities can 
result in different surface properties.74 For example, hydrophobic SAMs can promote 
cell adhesion, whereas SAMs with ethylene glycol moieties in the terminal groups 
resist protein adsorption and prevent cell adhesion.73-75 Therefore, the interactions 
between the cells and their microenvironment can be regulated by controlling the 
surface properties. 
 
Recently, the technique of microcontact printing is widely used for patterning 
different surfaces for cell attachment.31, 64, 73 Briefly, microcontact printing is the 
process of stamping proteins or peptides onto the surface of a substrate, leaving 
microscale features.76 Cells can attach to the features and their behaviors can be 
precisely controlled (Fig. 6).77 The features on the stamp can be generated using 
photolithography technique. The stamp can be made from a silicon wafer, a glass slide 
or a polymer, etc. 
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 C
Figure 6: microcontact printing (A) schematic of the microcontact printing on surfaces (B) 
Endothelial cells plated onto islands of ECM assume the geometry of the stamped region (C) 




Greatly benefitted from microfabrication technology, the microscale features 
generated on the surfaces of the cell culture substrates allows recapitulation of the 
microenvironment at cellular levels and thus cell functions are greatly enhanced for 
various applications.78 Therefore, microfabrication technology has drawn increasing 
attention as a novel tool for controlling the cellular microenvironment.79, 80 
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2.2 Microscale cell cultures for controllable cellular microenvironment 
Microscale systems can present cells within their microenvironment in a controllable 
and reproducible fashion that cannot easily be achieved by conventional tissue culture 
methods.81 Some microscale cell culture systems represent the miniaturizations of a 
wide range of biological systems,82, 83 whereas others focus on low Reynolds numbers 
for obtaining controllable laminar flows which are common in the microcirculations 
in vivo.15 Cells cultured in microscale systems can be easily incorporated into 
micro-total analysis systems (μ-TAS) that includes cell culture, cell sorting and 
analysis in one device to probe the biochemical processes that govern cell behaviors.84, 
85 The compact size of microscale systems allows researchers to use only a tiny 
amount of sample and reagent. Moreover, these systems allow easy scaling-up and 
mass productions, which minimize batch-to-batch variations and make the 
experimentations inexpensive.86 This section reviews the fabrication technology for 
microscale cell culture systems, highlighting microfluidics as a promising platform 
for cell cultures as well as creating soluble microenvironments for applications such 
as drug testing. 
 
2.2.1 Microtechnology for engineering microscale cell culture systems 
The microfabrication technology enables microscale features to be manufactured in 
the electronic devices and it relies heavily on cleanroom facilities, which can be found 
in the semi-conductor industry.64 This technology is now exploited to the biological 
field to generate micropatterned surfaces for fundamental studies in cell biology and 
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tissue engineering.81 The core technique to generate patterns is named 
photolithography.87 In this technique, with the help of light exposure, photoresist and 
masks, micropatterns can be obtained (Fig. 7). The photoresist is normally applied on 
a surface and exposed to UV light through a mask with the desired features. The UV 
exposed part of the photoresist is then washed off in a developer solution, giving rise 
to a photoresist pattern. Subsequently, the materials of interest (e.g. collagen, 
fibronectin, or Matrigel, etc.) are applied on the surface without photoresist, 
generating the particular pattern. Finally, the desired pattern of the material which 
cells are specifically adhered to is obtained.66 Cells can be seeded on the pattern for 
further studies.  
Silicon wafer 
Coating of photoresist 
Features protected by photomask 
Etching the wafer 
Stripping away the photoresist  
Figure 7: schematic of generating micropatterns using photolithography technique 
 
Photolithography technique is usually applied on hard surfaces and the reagents are 
toxic to cells, thus the biocompatibility is low.64 To solve this problem, the technique 
of soft lithography is developed to allow soft elastomeric material to be used for 
pattern transfer. The soft lithographic techniques mostly use poly(dimethylsiloxane) 
(PDMS), since it is biocompatible, optically transparent, gas permeable and durable.76, 
88 The most commonly used patterning methods involving PDMS are microcontact 
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printing and replica molding.76 
 
a) microcontact printing 
Instead of patterning a surface using photoresist, PDMS can be used as a stamp to 
pattern the material of interest onto a substrate surface (Fig. 8). The PDMS stamp is 
usually prepared from a master, which is fabricated using photolithography. The 
microcontact printing normally provides the patterning of SAMs (e.g. alkanethiol) to 
control the adsorption of subsequent proteins of interest to facilitate the patterning of 
cells on surfaces.89, 90 
 
Figure 8: schematic of microcontact printing using PDMS as a stamp.90
 
b) replica molding (REM) 
Replica molding is the process of duplicating information in the surface of a mold. It 
allows precise duplication of complex structures in multiple copies with micro or 
nanometer resolution in a fast, reliable, and simple way. Elastomeric material such as 
PDMS can be used to mold against rigid molds which were earlier fabricated using 
photolithography technique (Fig. 9). 
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 Figure 9: schematic of REM 
 
2.2.2 Microfluidics as a cell culture platform 
Microfluidics usually refers to liquid streams generated by the microscale channels in 
chips. It includes fabrication, handling and practical use of the chips. Streams of gases 
or fluidized solids/particles in microscale are also considered a form of microfluidics. 
64, 91 
 
Microfluidic channels can be obtained by contacting or bonding a substrate surface 
with channel structures in PDMS and these channels allow fluid delivering.17, 92 The  
flow inside microfluidic channels are always laminar, meaning that when two or more 
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streams of different flows meet inside a single channel, the mixing only takes place by 
diffusion at the interfaces.93 This phenomenon indicates the possibility to pattern cells 
and their environments using parallel streams of different solutions in 
microchannels.15, 94 Among all the patterning methods, this is the only method that 
allows spatial control of the cells in a highly controlled fashion.73 This method can 
also be used to study the subcellular processes by placing the interface of two adjacent 
streams over a single spreaded cell at the bottom of the microchannel.93 Two different 
dyes or reactants can be addressed to different regions of the single cell to observe 
different behaviors. Fluid flow in microfluidic devices also mimics vasculature found 
in biological systems,95 therefore the incorporation of fluid flow in cell culture allows 
efficient mass transfer between the cells and culture medium, maintaining a constant 
cell culture microenvironment.96, 97 Cellular functions can thus be enhanced in fluidic 
systems compared to conventional static cell cultures.17 In microfluidic systems, fluid 
flow applies fluid shear stress (FSS) on the cells. It is represented by Newton’s law of 
viscosity (Equation 1): 98 
d
dx
ντ μ= −   (1) 
Where τ is the shear stress, μ is the fluid viscosity, ν is the fluid velocity, and x is the 
position in the microfluidic channel. 
 
FSS can govern cellular behaviors inside microfluidic system. It induces the 
reorganization of the cytoskeleton and it is found that endothelial cells and BMSCs 
are able to align in the direction of the shear vector.99 Also, primary rat hepatocytes 
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are known to be very sensitive to FSS, where a FSS higer than 5 dyns/cm2 can impede 
their liver-specific functions.100 FSS also plays a role in the extravasations of tumor 
cells as it is observed that tumor-endothelial cell interactions are dependent on 
shear.101 
 
To control the FSS in the microfluidics, we can specifically design the geometry of 
the system to ensure low or high FSS.102 Also, microstructures (e.g., micro-grooves) 
can be incorporated to shield cell cultures from fluid flow.103 The FSS can be 




μτ =  (2)                           
Where τ is the shear stress, μ is the fluid viscosity, Q is the flow rate, h is the channel 
height, and w is the channel width. To reduce FSS inside microfluidic channels, flow 
rate can be reduced, or the channels can be designed higher or wider.  
 
Microfluidic systems can be interesting platforms for fundamental biological studies 
such as the hepatitis B viral repilication104 or the axonal injury, regeneration and 
transport in the central nervous system (CNS).105 Also, many microfluidic-based 
systems have been developed as novel cell culture platforms. For instance, a 3D 
microfluidic cell culture system (3D-μFCCS) was developed as a versatile system for 
culturing primary cells, stem cells and cell lines in 3D.17 An artificial liver sinusoid 
with a microfluidic endothelial-like barrier was able to support high-density primary 
hepatocyte culture and the viability of the hepatocytes remained high after 7 days.83 
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Moreover, a microscale cell culture analogue (μCCA) was developed to culture 
multiple cell types at a time to mimic the human physiology for pharmacokinetic 
testing.18, 106 
 
2.2.3 Controlling the soluble microenvironment in microfluidics 
Bioactive soluble factors in the microenvironment such as cytokines and growth 
factors, must be properly regulated as they are involved in autocrine and paracrine 
signalling pathways, which control cell behaviors, such as differentiation (e.g. sonic 
hedgehog,107, 108 bone morphogenetic proteins109, 110), proliferation (e.g. bFGF111), and 
apoptosis (e.g. TGF-β1112). However, it is difficult to temporally and spatially control 
the soluble factors in culture medium under conventional static cell culture conditions 
due to the large liquid volumes, the deactivation of growth factors and the continuous 
accumulation of metabolic waste.113  
 
Microfluidics, on the contrary, allows temporal and spatial control over the soluble 
microenvironment as a result of the nature of laminar flow.15, 93, 94 As mentioned in 
the previous section, the laminar flow within microfluidic channels can be used to 
control the positioning of soluble factors relative to cells.15 An individual cell can be 
exposed to multiple soluble microenvironments simultaneously by being placed at the 
interface between two or more adjacent streams. With the incorporation of gradient 
generators into microfluidic channels, a range of concentrations of soluble factors can 
be generated by merging, mixing and splitting of two or more streams from inlet, each 
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of which contains a particular stimulus.81 Therefore, different growth conditions can 
be created in parallel or in different combinations.114 Such gradients have been used to 
study cell chemotaxis such as IL-8. Insights into the migration of neutrophils as a 
result of various concentrations of IL-8 were gained.115 Also, in a hepatotoxicity study, 
a gradient generator was coupled to a microfluidic cell culture device to generate 
different concentrations of a drug for determining its IC50 value.116 
 
Many other microfluidic culture parameters could also affect the soluble factor 
signaling, which could be cell density, exogenous growth factors, medium change 
frequency or even culture platforms.98 Therefore, all these parameters have to be 
taken into consideration when culturing cells in a microfluidic device with spatial and 
temporal control of the soluble microenvironment.  
 
Due to the high surface to volume ratio in microfluidics, the soluble factors can be 
presented in a more physiologically relevant context,81, 117 providing a more in 
vivo-like cell culture. In key areas of drug discovery, such as preclinical testing of 
drugs in living cells, microfluidic tools can make a useful contribution.86 Their 
biomimetic nature enables more convincing drug testing data to be collected and their 
microscale size allows easy scaling-up and hence high-throughput drug 
screening.118-120 These advantages are not to be found in other conventional cell 
culture systems. 
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2.3 Controlled-release technique and the cellular microenvironment 
The technique of controlled-release could address several challenges with regard to 
sustained delivery of pharmaceuticals, peptides, proteins or nucleotides in a 
convenient and controllable manner, so that denaturation during storage or after 
administration in the body could be avoided.22, 121 A variety of methods have been 
developed to engineer the controlled-release systems with reproducible and 
predictable release kinetics. These methods include diffusion-controlled, water 
penetration-controlled, chemically-controlled or responsive systems.122 
 
There have been a number of research reports on protein release from polymer 
matrices such as poly(L-lactic acid) (PLLA) and its copolymers with poly(L-glycolic 
acid) (PLGA).123 Some ECM-derived proteins, such as collagen, gelatin and fibrin are 
also regarded as biocompatible materials for the fabrication of carriers.121, 123 Gelatin, 
a biodegradable material originated from collagen, is a widely used material for in 
controlled-release carriers.124-126 It is reported that carriers made of gelatin could 
enhance the bioavailability of calcitonin after nasal and intramuscular administration 
to rats.127 Gelatin has already been used as plasma expander128 and excipient for drug 
formulation.129 Recently, they were used clinically as implanted formulations for the 
target delivery of growth factors to promote bone regeneration.130  Controlled-release 
technology is usually synergized with various way of creating microenvironments in 
tissue formation. In this section, gelatin as a delivery vehicle for the controlled-release 
of bioactive molecules will be reviewed. 
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 2.3.1 Gelatin as carriers for polyion complexation 
Gelatin is a polymer derived from collagen. Different collagen pretreatments result in 
two types of gelatin.131 The alkaline pretreatment targets the amide groups of gelatin 
and hydrolyses them into carboxyl groups, converting these amide groups into 
aspartate or glutamate. In contrast, acidic pretreatment does not affect the amide 
groups presented.123, 131 
 
Gelatin processed under an alkaline pretreatment is electrically different from the 
acidic processed one. The alkaline-pretreated gelatin has a greater proportion of 
carboxyl groups, making it become negatively charged and with low isoelectric point 
(IEP). On the contrary, acidic-pretreated gelatin possesses an IEP similar to 
collagen.123 Gelatin carriers form polyion complexations with their therapeutic agents, 
depending on the surface charge of the agents. In general, acidic gelatin with an IEP 
of 5.0 should be used for basic proteins, while basic gelatin with an IEP of 9.0 should 
be used for acidic proteins under physiological conditions.131 
 
Before in vivo or in vitro applications, gelatin has to be cross-linked to improve its 
thermal and mechanical properties under physiological conditions (e.g. insoluble in 
water as carriers). The cross-linking can also efficiently control the rate of its 
degradation.132 Both physical and chemical methods can be employed to cross-link 
gelatin. Physical methods include UV-irradiation and dehydrothermal treatment123 
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whereas chemical methods involves reagents such as glutaraldehyde (GA), 
polyepoxides and isocyanates.133 The properties of cross-linked gelatin are highly 
dependant on its cross-linking density. The higher the cross-linking density, the better 
the mechanical stability will be. As a result, the gelatin will be more difficult to 
degrade and the release rate will be relatively low.131, 133 Higher concentration of 
cross-linking reagents and a prolonged cross-linking time will usually lead to a high 
cross-linking density of gelatin.131, 133 
 
Loading biomolecules into gelatin carriers is the formation of polyion complexation. 
Biomolecules and gelatin with opposite charges can be pulled together and the 
biomolecues can be adsorbed onto gelatin surfaces.121, 123 To load the biomolecule, its 
solution can be prepared and dropped onto freeze-dried gelatin carriers, allowing for 
sorption.134 Also, gelatin carriers can be soaked in the solution of the biomolecules for 
a period of time to allow molecule loading. 
 
2.3.2 Different gelatin matrics for controlled release  
Gelatin carriers are widely used for controlled-release of biomolecules in vivo to 
facilitate tissue formation (e.g. bone tissue formation,135 ligament and adipose tissue 
regeneration,136, 137 neovascularization138). It can also be employed for gene therapy 
where nucleic acids are released. Loading therapeutic drugs to gelatin carriers also 
made bone infection treatment139 or cancer chemotherapy possible.140 Gelatin carriers 




After the cross-linking process, gelatin aqueous solution turns into hydrogel. When 
the residual cross-linking reagent is removed, gelatin hydrogels can be shaped into 
sheets, disks, cubes or strips by stretching, punching or cutting.123, 131 The gelatin 
hydrogels can then be loaded with target biomolecules for implantation. Compared to 
gelatin block hydrogels, porous gelatin scaffolds are more well-suited for tissue 
engineering applications due to their increased surface area, which allows high 
density cell seeding, rapid degradation of the scaffold and encourages tissue in-growth 
and vascularization of the tissue after implantation.123 The fabrication of porous 
scaffold requires one more step after gelatin block hydrogels are formed, which is 
freezing. Ice can facilitate the formation of porous structures and hence a porous 
scaffold.141 Both gelatin hydrogels and scaffolds require invasive surgical procedures 
for implantation and to make it less invasive, injectable matrices such as GMs were 
fabricated. GMs are formed by a water-in-oil emulsion technique.121 Briefly, gelatin 
solution is added dropwise into olive oil under continuous stirring and gelatin droplets 
can be formed. After cross-linking, freeze-dry and sterilization, the GMs are ready for 
use. 
 
2.3.3 GMs as novel controlled release carriers 
Classic examples of the applications of GMs have been found in hard/soft tissue 
engineering. When the GMs are embedded on the synthetic polymer 
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(oligo(poly(ethylene glycol) fumarate) (OPF), they are able to be implanted and 
controlled-release bioactive molecules in vivo. TGF-β1 and insulin-like growth 
factor-1 (IGF-1) were loaded onto GMs for sustained release. They can be delivered 
to the cartilage lesions through the GMs. TGF-β1 has been shown to promote the 
chondrogenic differentiation of progenitor cell, increase cartilage ECM synthesis, and 
enhance chondrocyte proliferation, while IGF-1 has been reported to enhance 
proteoglycan and type II collagen synthesis.142 In another study, preadipocytes 
isolated from adipose tissue were implanted together with bFGF-loaded GMs in nude 
mice. After 6 weeks of implantation, adipose tissue formation was observed.136 A 
similar model has been used to regenerate periodontal ligament tissue.137 
bFGF-loaded GMs were implanted at the bone defects of beagle dogs and after 4 
weeks, vascularization and osteogenesis were observed, with histological staining 
indicating the functional recovery of periodontal ligament tissue.137 The ability of 
GMs to serve as carriers for bioactive molecules and its simplicity for injection give it 
great potential for use as a controlled-release vehicle in tissue engineering 
applications. 
 
GMs are also useful in other applications such as gene delivery. Compared to 
traditional viral vector as a gene delivery vehicle, GMs will not cause any side effects 
such as immunological responses or toxicity.123 They are easy to fabricate and can 
improve the transfection efficiency. It is already shown that GMs are able to load and 
controlled-release plasmid-DNA in vivo.143  
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 Apart from delivering bioactive molecules, GMs are also capable of delivering drugs 
for disease treatment. They are found to be able to controlled-release antibiotics such 
as tetracycline and bisphosphonate to reduce periodontal bone loss in vivo.144 Studies 
on GMs as a controlled-release vehicle for chemotherapeutic drugs were also reported. 
By localized delivery of an anti-cancer drug to the vicinity of a tumor, the drug 
dosage required in the body for efficient treatment would be decreased, also 
decreasing the chances of side effects for the patient. GMs have already been proved 
to be good candidates for sustained release of colchicine, an antimitotic drug for 
curing tumors.140 Since gelatin is a biocompatible material and GMs are found 
capable of delivering many types of bioactive molecules such as growth factors, they 
possess interesting features to be easily incorporated into various in vitro cell culture 





2.4 Limitations of current studies and rationale of thesis research 
Highly functional in vitro cultured cells are of great usefulness in various applications 
such as cell-based testing, constructing large tissues and pathological research.24 The 
key to culturing functional cells in vitro is to recapitulate an in vivo-like cellular 
microenvironment which allows extensive mechanical support as well as cell-cell, 
cell-matrix and cell-soluble factor interactions.1, 13, 145 Compared with scaffolds or 
hydrogels, microfluidic platform has a lot of potential in downstream applications for 
a controllable microenvironment, due to the microscale dimension and the consistent 
laminar flow environment. However, a single strategy (i.e., microfabricated 
wells/chambers or cell-encapsulating 3D matrix) cannot fulfill all the requirements for 
constructing an in vivo-like microenvironments and they face several limitations. For 
instance, as mentioned in section 2.2.2, a μCCA was developed to culture three cell 
types simultaneously with one common medium perfusion (Fig. 10),18, 106 which is to 
mimic the physiology in vivo for pharmacokinetic testing. However, the cells were 
cultured in the μCCA based on 2D monolayers and no specific microenvironment was 
presented to the cells for their functional enhancement, which might impede 
evaluating the systemic effect of a drug. Although many microfluidic cell culture 
systems have been engineered for controlling 3D cell-matrix and cell-cell 
interactions,16, 17, 83 few attempts to engineer a soluble microenvironment for extensive 




Figure 10: the μCCA. Lung cells (L2), liver cells (HepG2/C3A) and fat cells (3T3-L1) were 
o establish a soluble microenvironment within microfluidics, gradient generators can 
be incorporated. However, when designing gradient generators, some parameters have 
to be taken into consideration, such as transport phenomenon and shear stress.98 It 
needs a lot of expertise to design, fabricate and operate these integrated devices.  
 
On the other hand, as mentioned in section 2.3.3, GMs are found capable of delivering 
many types of bioactive molecules such as growth factors. Gelatin is a biocompatible 
material which will not cause side effects to the cells. Due to the microscale sizes of 
GMs, they can be easily introduced into microfluidic systems and generate a constant 
soluble microenvironment in situ. The design and operation of the system can be 
much simpler than handling gradient generators. In this thesis, the focus is on 
engineering constant microenvironments, especially soluble microenvironments in 
microfluidic systems using controlled release technique. The rationale for 
incorporating the features is as follows: 
cultured in the μCCA to mimic lung, liver and fat. The geometry of the cell culture 
compartments were designed to ensure that blood residence time (culture medium in this case) 




Use of microfluidic channels: 
z Due to the laminar flow environment in microfluidic channels, they allow 
for an unprecedented opportunity to control cellular microenvironment. 
z Fluid flow allows enhancement of oxygen and nutrients delivery as well as 
metabolic waste removal. Therefore, it ensures a constant culture 
microenvironment compared to static culture. 
z We have already developed a 3D-μFCCS to establish extensive cell-matrix and 
cell-cell interactions in vitro. 
z This transparent platform allows for optical interrogations, hence providing a 
spatial-temporal resolution to study cellular behavior in response to external 
stimuli.  
z The microfluidic channel offers opportunity to be multiplexed for 
high-throughput applications such as drug-testing. 
Use of control release technology: 
z The release of the encapsulated molecules could be sustained over a long period 
of time, without their chemical properties being disturbed in a fluidic 
environment.  
z The GMs can be entrapped in the 3D-μFCCS, thus creating a localized soluble 
microenvironment in situ. 
z Gelatin is an excellent material as a controlled release carrier due to its 
biocompatibility, biodegradability and enhanced bioavailability of the 
encapsulated molecules. 
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CHAPTER 3 Objectives and Specific Aims 
This thesis aims to engineer a soluble microenvironment in microfluidic systems, 
which is considered an important factor for creating in vivo-like microenvironments 
for cell culture and cellular function enhancement. A 3D-μFCCS has already been 
developed in our group as a generic cell culture platform. In this 3D-μFCCS, cells can 
be cultured in a 3D fashion, allowing extensive cell-cell interactions. Also, to 
establish matrix support for the cells, complex coacervation of collagen was formed 
via hydrodynamic focusing, mimicking the ECM in the cellular microenvironment. 
We aim to further create a soluble microenvironment by incorporating growth 
factor-releasing GMs into the 3D-μFCCS. Characterizations of the GMs have been 
performed to ensure that its fabrication, controlled-release properties and 
incorporation into the 3D-μFCCS can be well controlled. In the engineered soluble 
microenvironment, the functions of primary rat hepatocytes were found to be 
significantly enhanced after 7 days of culture and so was their sensitivity to 
drug-mediated hepatotoxicity. Also, the soluble microenvironments can be 
individually controlled when multiple cell types were cultured simultaneously in a 
multi-channel 3D-μFCCS. The functions of all cells were enhanced, which is critical 
for downstream applications such as pharmacokinetic testing. All these efforts are 




3.1 Specific Aim 1: To fabricate, characterize and incorporate GMs into the 
3D-μFCCS to ensure the feasibility of this strategy for engineering a soluble 
microenvironment 
Hypothesis 
The soluble microenvironment can be created by controlled-releasing biomolecules 
from the GMs and it is dependant on the properties as well as the incorporation 
process of the GMs into the 3D-μFCCS. 
Rationale 
It is already shown that microfluidic system can provide a more controllable and 
constant microenvironment for cell culture. To establish cell-soluble factor 
interactions in microfluidic systems, external gradient generators can be 
incorporated.146-148 However, the use of gradient generators are usually coupled to 
some of the issues such as shear stress and transport phenomenon, which are critical 
to cellular functions.98 Also, the design and handling of gradient generators needs a lot 
of expertise. Most soluble factors such as growth factors have very short half-lives 
and their activities cannot be properly protected by gradient generators. Hence, a 
method that  
1) is simpler than the incorporation of gradient generators, 
2) allows the presence of active soluble factors, 
3) is compatible with the 3D-μFCCS, 
4) allows precise control over the soluble factors, 
would be helpful for engineering a soluble microenvironment. Here we aim to 
incorporate soluble factor releasing-GMs into the 3D-μFCCS for the engineering of 
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the soluble microenvironment. GMs can prolong the activity of the soluble factors and 
release them at a certain rate (it can be controlled by the cross-linking density and 
stirring rate during fabrication).121 The microscale size of the GMs allows the 
simplicity of their incorporation into the 3D-μFCCS and thus the creation of a 
constant soluble microenvironment in situ. By controlling the parameters in the GM 
fabrication process as well as the fluidic conditions in the 3D-μFCCS, the soluble 
microenvironment can be manipulated. 
Experimental design 
z Design, synthesis and characterization of the GMs 
z Optimization of the controlled-release properties of the GMs by controlling the 
cross-linking density and stirring rate during fabrication 
z Optimization of the “cell number/GM ratio” for successful incorporation of the 
GMs into the 3D-μFCCS 




3.2 Specific Aim 2: To access the engineered soluble microenvironment in the 
3D-μFCCS for functional enhancement of primary rat hepatocytes 
Hypothesis 
Primary rat hepatocytes cultured in its specific soluble microenvironment will exhibit 
enhanced liver-specific functions and hence a higher sensitivity to drug-mediated 
hepatotoxicity. 
Rationale 
The engineering of a soluble microenvironment using our method is only useful when 
the cells cultured in a specific microenvironment can exhibit enhanced biological 
activities. Here, primary rat hepatocytes cultured in the 3D-μFCCS without a soluble 
factor was used as the control. This is to determine if 
1) the presence of soluble factors can indeed enhance the liver-specific functions of 
primary rat hepatocytes 
2) the engineered soluble microenvironment can further enhance the liver-specific 
functions and increase the sensitivity of primary rat hepatocytes 
Highly functional primary rat hepatocytes are a good cell model for many cell-based 
applications such as drug-testing149 or the engineering of liver-assist devices.150, 151 
However, their functions tend to rapidly lose under standard in vitro cell culture 
conditions.152 So far, the most efficient in vitro culture method to maintain hepatocyte 
functions is co-culture, in which primary hepatocytes are supported by the soluble 
factors secreted by the non-parenchymal cells in the culture, such as TGF-β1 secreted 
by fibroblasts.65, 66, 153 The characterization of liver-specific functions such as albumin 
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secretion, phase I/II enzymatic activities are well established.37, 116 Here we check the 
primary hepatocytes cultured under our engineered soluble microenvironment of 
TGF-β1 for these features. 
Experimental design 
z Optimization of the concentration of TGF-β1 for functional enhancement of 
primary hepatocytes 
z Optimization of the number of TGF-β1 releasing-GMs to be incorporated into the 
3D-μFCCS 
z Characterization of the liver-specific functions of primary hepatocytes cultured in 
the engineered soluble microenvironment of TGF-β1 
○ Cytochrome P450 1A1/2 enzymatic activity 
○ Umbelliferone glucoronide transferase (UGT) enzymatic activity 




3.3 Specific Aim 3: To create individually controlled soluble microenvironments in 
a multi-channel 3D-μFCCS for functional enhancement of multiple cell types 
Hypothesis 
Using the controlled-release technique in a multi-channel 3D-μFCCS, the created 
soluble microenvironment can be localized in its corresponding cell culture 
compartment for the functional enhancement of cells. 
Rationale 
Compared to in vivo models, integrated devices for culturing multiple cell types to 
study the systemic effect of chemicals in vitro can help accelerate the screening 
process, reduce the cost in early drug development and they will not give rise to 
cross-species extrapolation problems.154 In order for the in vitro model to provide 
closer prediction to in vivo responses, the engineering of these models have to  
1) be able to culture multiple cell types simultaneously to study the systemic effect of 
a chemical 
2) be able to maintain highly level of cellular functions to provide convincing data 
3) mimic some important features found in vivo, such as blood circulation, 
diffusion-controlled mass transfer between blood and organ and limited cross-talk 
between different organs 
Therefore, in this aim, we multiplexed our 3D-μFCCS into a multi-channel 
3D-μFCCS to culture four different cell types to mimic four human organs: C3A 
(liver), A549 (lung), HK-2 (kidney) and HPA (fat). The four cell types were chosen 
for our study because they exhibit their organ-specific functions and have been widely 
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used for many applications such as drug testing (C3A)155 and toxicity testing of 
nanoparticles in air (A549).156 We tested the feasibility of culturing four cell types 
simultaneously in the multi-channel 3D-μFCCS and found that TGF-β1 has 
differential effects on different cell types. We thus controlled-released TGF-β1 in the 
A549 compartment and checked the feasibility of minimizing cross-talks between 
different compartments by evaluating the functions of other cell types. 
Experimental design 
z Optimization of a common, serum-free culture medium for enhancing the 
functions of four cell types 
○ Albumin secretion (C3A) 
○ pentoxyresorufin O-dealkylation (PROD) enzymatic activity (A549) 
○ gamma-glutamyl transferase (GGT) enzymatic activity (HK-2) 
○ Adiponectin secretion (HPA) 
z Evaluation of the differential effects of TGF-β1 on four cell types 
z Controlled-release of TGF-β1 in its corresponding compartment and evaluation of 
the compartmentalized soluble microenvironment by measuring cellular functions 
of all the four cell types 
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CHAPTER 4 Fabrication, Characterization and Incorporation of GMs into the 
3D-μFCCS  
4.1 Introduction 
Creating cellular microenvironments in cell cultures enhances the cell functions and 
therefore improves cell-based applications such as tissue engineering or drug testing.2 
The cellular microenvironment includes cell-matrix, cell-cell and cell-soluble factor 
interactions which should be re-established in vitro. Many sophisticated micro- or 
nanofabrication techniques have been developed to facilitate creating the cellular 
microenvironment.73, 74, 79, 103 In particular, the emergence of microfluidic cell culture 
devices made possible the creation of entire blood supply when constructing a large, 
complex tissue in vitro.95 Also, it has enabled novel experimentation in controlling the 
cellular microenvironment and phenotypes.157 Microfluidic devices allow spatial and 
temporal control over the biochemical signals in the microenvironment.15, 93 We have 
previously developed a novel 3D-μFCCS, which allows cells to experience 
engineered 3D cell-matrix and cell-cell interactions in a perfused fluidic 
environment.17 3D cell-matrix interactions were achieved by the formation of a 3D 
matrix via the complex coacervation of a pair of polyelectrolytes (i.e., positively 
charged methylated collagen and negatively charged acrylate-based terpolymer) under 
laminar flow conditions. 3D cell-cell interactions were achieved by immobilizing cells 
within the microfluidic system with a micropillar array. The versatility of the 
3D-μFCCS was demonstrated by the successful culture and functional maintenance of 
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multiple cell types.  
 
To further create cell-soluble factor interactions in the 3D-μFCCS, we aim to 
introduce soluble factors. However, soluble factors usually have very short half-lives 
and the activities are difficult to preserve. To prolong their activities, loading them 
onto controlled-release carriers is the most efficient method.122 Many types of 
controlled-release carriers have been developed for controlled-releasing various types 
of molecules, such as chemicals, soluble factors or even genes.123, 131 We chose gelatin 
as the material for fabricating GMs as the controlled-release carrier. It is derived from 
collagen and is biocompatible.131 When degraded, gelatin will not give rise to acidic 
bi-products as PLGA does.121 The fabrication of GMs is easy and the properties (i.e. 
size, degradation rate, controlled release rate) of the GMs can be controlled during 
fabrication. With the incorporation of GMs in the 3D-μFCCS, the soluble 
microenvironment can be formed on chip. By varying the number of GMs in the 
3D-μFCCS, the concentration of the soluble factors in the microenvironment can be 
controlled. 
 
In this study, we further validated our 3D-μFCCS as a versatile cell culture platform 
for various cell types. GMs with different sizes and controlled-release rate were 
fabricated under different conditions. The conditions for successfully immobilizing 
GMs with cells in the 3D-μFCCS were optimized and we found that the number of 
GMs in the 3D-μFCCS can be precisely controlled. Our characterization indicated 
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that a constant soluble microenvironment can be created even with fluidic perfusion. 
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4.2 Materials and Methods 
4.2.1 Device fabrication 
Microfluidic channels with micropillar arrays were designed using AutoCAD 
(Autodesk, USA) as previously described.16 Silicon templates were fabricated by 
standard photolithography which involved photoresist application (AZ 4620, 
Germany), UV light exposure, development and deep reactive ion etching (DRIE) 
process (Alcatel, France). The microfluidic channels were then obtained by replica 
molding PDMS (Dow Corning, USA) on the silicon templates. Holes were made 
using a puncher (Innovative Technology, USA) for connecting tygon tubing (Fisher 
Scientific, USA) via small metal tubings (New England Small Tube Company, USA) 
to the microfluidic device. The PDMS structures were plasma-oxidized for 1 minute 
(125 W, 13.5 MHz, 50 sccm, and 40 millitorr, SAMCO, Switzerland) for irreversible 
bonding to glass coverslips. One inlet of the microfluidic channel was connected to a 
cell reservoir, which comprised of a two-way valve with a luer connection 
(Cole–Palmer, USA) coupled to a 22G stainless steel hypodermic needle 
(Becton–Dickinson, USA). The other inlet and the outlet were for cell culture medium 
perfusion. All other fluidic connectors were from Upchurch (USA). The entire set-up 
was sterilized by autoclaving it at 105 ºC for 30 min. 
 
4.2.2 Fabrication of GMs 
GMs were fabricated via glutaraldehyde crosslinking of a gelatin aqueous solution, 
using a water-in-oil emulsion technique. To create the water-in-oil emulsion, 4 g of 
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gelatin (Sigma, USA) was dissolved in 4 ml of deionized (DI) water to a final 
concentration of 10% wt. and 10 μl of 10% glutaraldehyde was added into the gelatin 
solution. The solution was preheated to 37 ºC and added dropwise into 300 ml of olive 
oil under continuous stirring at 2000 rpm for 10 minutes. Spontaneous gelation of the 
gelatin droplets was then driven by a 15 ºC decrease in emulsion temperature 
followed by 24 hours of agitation at 2000 rpm. The resulting microspheres were then 
washed in acetone and recovered by centrifugation at 5000 rpm at 4 ºC for 8 minutes. 
This recovery process was repeated five times. The crosslinking reaction was then 
quenched by agitating the microspheres in 100 mM aqueous glycine solution (Sigma, 
USA) for 1 hour. Lastly, the microspheres were washed three times with DI water and 
lyophilized. The microspheres were sterilized by washing with 99% ethanol and 1× 
sterile PBS before used. 
 
4.2.3 Characterization of FITC-dextran release profile from the GMs 
The amount of FITC-dextran released from the GMs was assessed by measuring the 
fluorescent intensity of FITC-dextran in the solutions. 9.5 KDa, 70 KDa and 150 KDa 
of FITC-dextran were dissolved in 1×PBS solution. 1.6 mg of GMs was soaked in 0.1 
ml of 0.1 mg/ml FITC-dextran solution at 4 ºC overnight for loading. The entrapment 
efficiency was about 40%. To determine the release profile, the FITC-dextran-loaded 
GMs were spinned down at 5000 rpm for 5 minutes and the supernatant was collected. 
Another 0.1 ml of 1×PBS was added to the GMs for continuous releasing. This was 
repeated on a daily basis for 7 days. The fluorescent intensity of the supernatant was 
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measured using a microplate reader (TECAN, Switzerland) to determine the release of 
FITC-dextran from GMs. 
 
4.2.4 Polyelectrolytes fabrication 
Methylated collagen and terpolymer of hydroxylethylmethacrylate– 
methylmethacrylate–methylacrylic acid (HEMA-MMA-MAA) were synthesized, 
purified and characterized as described previously.37 Dr. Tang Guping’s lab (Zhejiang 
University, China) has helped with the synthesis and characterization of the 
terpolymer. 3% terpolymer solution and 1.5 mg/ml methylated collagen were used in 
this thesis. 
 
4.2.5 Seeding GMs in the 3D-μFCCS 
To immobilize the FITC-dextran releasing GMs in the 3D-μFCCS, the GM 
suspension was withdrawn from the cell reservoir, via the outlet, using a withdrawal 
syringe pump (Cole-Parmer, USA). Laminar flow complex coacervation was 
implemented as described previously.37 The 3D-μFCCS was kept on a heater plate 
(MEDAX, Germany) at 37 ºC, with PBS perfused continuously at 0.05 ml/h. The 
perfusate was collected daily for assessment of fluorescence intensity. 
 
4.2.6 Cell maintenance 
All cell culture components are purchased from GIBCO, Invitrogen, USA unless 
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otherwise stated. L2, A549 and 3T3-L1 (ATCC, USA) were cultured in 
DMEM/F12-K (1:1) supplemented with 10% fetal bovine serum, 1.5 g/L sodium 
bicarbonate, 1 mM L-glutamine, 100 units/ml penicillin and 100 g/ml streptomycin. 
C3A (ATCC, USA) was cultured in MEM supplemented with 10% fetal bovine serum, 
1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 
g/ml streptomycin.  
 
4.2.7 Seeding of cells in the 3D-μFCCS 
~9-10 million L2, 3T3-L1, C3A and A549 cells were resuspended in 1 ml of 
methylated collagen solution. To immobilize the cells in the 3D-μFCCS, the 
suspension was withdrawn from the cell reservoir, via the outlet, using a withdrawal 
syringe pump (Cole-Parmer, USA). Laminar flow complex coacervation was 
implemented as described previously,17 followed by infusing culture medium for 
displacing excess polyelectrolytes. 
 
4.2.8 Cell viability staining 
Cell viability of A549, C3A, L2 and 3T3-L1 after 72 hours of perfusion culture in the 
multi-channel 3D-μFCCS was qualitatively assessed by perfusing 5 mM of Calcein 
AM (Molecular Probes, USA) and 25 mg/ml of PI (Molecular Probes, USA) at 0.9 




4.2.9 Seeding of GMs and cells in the 3D-μFCCS 
~9-10 million fixed C3A and 3000-9000 GMs were resuspended in 1 ml of 
methylated collagen solution. To immobilize the C3A/GM mixture in the 3D-μFCCS, 
the C3A/GM suspension was withdrawn from the cell reservoir, via the outlet, using a 
withdrawal syringe pump (Cole-Parmer, USA). Laminar flow complex coacervation 
was implemented as described previously,17 followed by infusing culture medium for 
displacing excess polyelectrolytes. 
 
4.2.10 Characterization of fluorescent intensity distribution in the 3D-μFCCS 
GMs were soaked and loaded with 5 μg/ml of Rhodamine B isothiocyanate-Dextran 
(Sigma, USA) with a molecular weight of 10 KDa at 4°C, overnight. Then C3A after 
fixation was seeded with the GMs in the 3D-μFCCS before imaging. Fluorescent 
images of the channel were acquired using an EMCCD camera (Cascade II: 512, 
Photoetrics, USA) mounted on the side port of an inverted epifluorescence 
microscope (Axiovert 200M, Carl Zeiss, Singapore), resulting in a 512 x 512 pixel 
image of 0.284 μm/pixel. Both camera and microscope were controlled by 
Metamorph (Universal Imaging Corporation, USA). A Zeiss HBO 100 mercury lamp 
was used to illuminate the device through a 60X oil objective (TIRF NA 1.45, 
Olympus, Singapore) along with a 560 DRLP dichroic and 595 AF560 emission filter 
(both from Omega Optical, USA). Exposure times for tranmission and fluorescence 
images were 100 ms and 5000 ms respectively. Subsequent analysis on the fluorescent 
images was performed with Matlab®. 
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4.3 Results and discussion 
4.3.1 Design and fabrication of the modified 3D-μFCCS 
Based on the 3D-μFCCS developed in our group, certain modifications have been 
done to make the system easier to handle. As shown in Fig. 11, the original 
3D-μFCCS has three inlets and three outlets (Fig. 11A), which are connected to many 
external devices (a valve and a flow splitter at the inlet and another two valves plus a 
flow merger at the outlet). The involvement of too many external devices complicated 
the operational procedures, increasing chances of mistakes in the process. Moreover, 
the incorporation of external flow splitters can increase the resistance in the set-up 
and hence chances of uneven flow in the two side channels (indicated by the red 
arrows in Fig. 11E), affecting cell viability or functions. In the modified 3D-μFCCS, 
there are only one inlet and one outlet, and the two side channels are initiated by an 
intrinsic flow splitter and they merge into a single outlet (Fig. 11B). This 
improvement could minimize the usage of external devices (only one valve at the 
inlet and one valve at the outlet) compared to the original design (Fig. 11C and 11D). 
Also, it reduced the possibilities of uneven fluid flow in the microfluidic channel. The 
cell reservoir is meant for cell seeding while the micropillar array in the center is 
meant for entrapment of cells. The geometry of the cell culture compartment 
remained unchanged.  
 
The size of the micropillars was designed to be 30 μm ×50 μm for efficient trapping 
of cells and mass transfer of nutrients. The shape and the angles of the pillars were 
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previous optimized to ensure maximal cell trapping efficiency without causing 
clogging. However, the size may vary slightly due to the fabrication process. It is 
closely related to the remaining photoresist on the silicon wafer before etching 
(indicated by white arrows in Fig. 12A and 12B). Therefore, by controlling the 
developing time of the photoresist, slightly different pillar sizes can be obtained. For 
instance, to get smaller pillars, the developing time can be 1 minute and it can be 1.5 
minutes for bigger pillars (Fig. 12C and 12D). Pillar sizes are important for cell 
seeding. For small cells with an average diameter of less than 10μm (e.g. C3A), 
bigger pillars can ensure more efficient packing of cells while smaller pillars can be 
used for packing relatively bigger cells (e.g. HK-2). 
 
 
Figure 11: schematic representation of the microfluidic channels. (A) the original microfluidic 
channel (B) the modified microfluidic channel (C) the connections and connectors needed for 
the original microfluidic channel (D) the connections and connectors needed for the modified 





Figure 12: different sizes of the micropillars due to the fabrication (A, B) the photoresist 
cover the pattern of the 3D-μFCCS and the thickness of the residual photoresist (indicated by 
white arrows) are related to varied pillar sizes. (C) bigger pillars due to relatively longer 
developing time and (D) smaller pillars due to shorter developing time 
 
4.3.2 Reducing the occurrence of air bubbles in the 3D-μFCCS 
Formation of air bubbles is a recurring problem in microfluidic systems. They will 
increase the resistance in fluid flow or even cease the flow; hence the viability and 
functionality of the cells will be affected. Degassing all the reagents can help reducing 
bubble formation to an extent. In addition, we found that the ports for connecting 
tubings are usually where bubbles originate (arrows in Fig. 13A). To minimize bubble 
formation, ports with smooth edges are preferred as compared to rough ones (Fig. 
13B and 13C) since rough ports are more prone to trapping or generating air bubbles 
(Fig. 13D and 13E). To obtain ports with smooth edges, a sharp puncher is required 
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when punching the ports. If small bubbles are found stuck in the ports (Fig. 13D), 
they can be collapsed by pressurizing the whole 3D-μFCCS. Bigger bubbles (Fig. 13E) 
are more difficult to be collapsed under high pressure. Therefore, they can be broken 
down into smaller ones by tapping and then be collapsed by pressurizing. 
 
 
Figure 13: Reducing bubble formation in the 3D-μFCCS. (A) The ports for tubing 
connections are the sites most prone to bubble formation. (B) Smooth edges of the ports are 
preferred over the (C) rough edges (black arrow). (D, E) Bubbles are found in the ports with 
rough edges in the 3D-μFCCS (black arrow and the circle with white dashed line). 
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4.3.3 Culturing of various cell types in the 3D-μFCCS 
To investigate the versatility of the 3D-μFCCS, we cultured four different cell types 
(L2, 3T3-L1, A549 and C3A) and evaluated their viability under confocal microscopy 
by live (green)/dead (red) staining after 3 days of perfusion culture. All the cells can 
form viable multi-cellular aggregates (stronger green signals than red signals), 
indicating that the cells can be maintained viable in the 3D-μFCCS with medium 
perfusion (Fig. 14A-D). In addition, multi-cellular aggregates of A549 and C3A cells 
exhibited rounded morphology with distinct cortical F-actin staining (Fig. 14E and 
14F), indicating that 3D cyto-architecture was maintained in the 3D-μFCCS, in 
contrast to the diffusive localization with stress fiber formation in 2D monolayer 















Figure 14: different cell types cultured in the 3D-μFCCS (A) L2, (B) 3T3-L1, (C) A549 and 
(D) C3A. (E) A549 and (F) C3A cells exhibited rounded morphology with distinct cortical 
F-actin staining, in contrast to the diffusive localization with stress fiber formation in 2D 
monolayer cultures (inserts at the up-left corner). 
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4.3.4 Fabrication conditions for GMs 
The GMs can be fabricated using the water-in-oil emulsion technique. Their 
controlled-release properties are closely related to the conditions and parameters 
during the fabrication. Two major parameters are involved in determining the GM 
properties. Firstly, the average size and morphology of the GMs can be controlled by 
the stirring rate during the emulsification process. Secondly, the cross-linking density 
of the GMs (in this case the concentration of the cross-linking agent, glutaraldehyde) 
governs their degradation rate as well as the controlled-release rate of molecules from 
them. In this study, we fabricated the GMs under two different stirring rate (700 rpm 
and 1000 rpm) and two different cross-linking densities (5% and 10%). The 
morphology of the GMs was observed under light-transmitted microscopy. At a fixed 
cross-linking density of 10%, a stirring rate of 700 rpm resulted in clumpy GMs and 
their sizes greatly varied. Also the GMs exhibited rough surfaces (Fig. 15A). On the 
contrary, under the stirring rate of 1000 rpm, the size distribution of the GMs was 
more even. Single and solid microspheres with rounded morphology and smooth 
surfaces were formed (Fig. 15B). Moreover, the diameters of the GMs fall within the 
range of 20-50 µm, which is ideal for them to be immobilized behind the micropillars 
of the 3D-µFCCS.  
 
In order to characterize the controlled-release properties of the fabricated GMs with 
both 5% and 10% cross-linking density at a fixed stirring rate of 1000 rpm, 
FITC-dextran with molecular weight of 9.5KDa, 70 KDa and 150 KDa was loaded 
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into the GMs as model molecules (Fig. 16). The accumulative amount of released 
FITC-dextran was measured for 5 days. On a daily basis, the amount of released 
molecule remains constant regardless of the molecular weight of the FITC-dextran 
and the cross-linking density of the GMs, indicating that the fabricated GMs were 
capable of releasing the molecules in a controlled and sustained manner. However, the 
exact amount of released FITC-dextran was closely related to their molecular weight 
as well as the cross-linking density of the GMs. With a 5% cross-linking density, the 
total released amount after 5 days was 4.5μg for 9.5 KDa FITC-dextran, 3.0μg for 70 
KDa and 1.7μg for 150 KDa (Fig. 16A). 10 % cross-linking density resulted in less 
amount of release FITC-dextran, with 2.3μg for 9.5 KDa, 1.7μg for 70 KDa and 0.7μg 
for 150 KDa (Fig. 16B). For subsequent studies, we chose the GMs fabricated with 
10% cross-linking density at a stirring rate of 1000 rpm. 
 
 
Figure 15: gelatin microspheres fabricated by a water-in-oil emulsion technique at the 



































































Figure 16: controlled-release property of the GMs with a cross-linking density of (A) 5% and 
(B) 10%. FITC-dextran of 9.5 kDa, 70 kDa and 150 kDa are used as model molecules. Data 
are mean ± S.E.M of 3 independent experiments. 
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4.3.5 Entrapment of GMs in the 3D-µFCCS 
The GMs are meant to be incorporated into the 3D-µFCCS to create soluble 
microenvironments. This is based on the hypothesis that the molecules released from 
the GMs could remain in the central compartment, defined by the micropillar array, 
rather than being removed by perfusion. In order to validate this hypothesis, we 
seeded the GMs (loaded with 70 KDa FITC-dextran) into the 3D-µFCCS and 
perfused the system with 1× PBS to mimic the fluidic environment (Fig. 17A). The 
PBS that came out from the microfluidic channel was collected to quantify the 
fluorescence intensity, which could reflect the amount of released molecules that was 
removed from the microfluidic channel.  
 
At the end of this perfusion experiment, the number of GMs in the 3D-µFCCS was 
quantified. According to this quantification, we measured the exact same amount of 
GMs (loaded with FITC-dextran) to quantify the amount of released FITC-dextran 
under static conditions. The static condition was set as a control. From Figure 10, it 
was observed that compared to perfusion, the amount of released FITC-dextran was 
much more under static conditions (represented by higher fluorescence intensity, 1000 
in static vs. 80 in perfusion) (Fig. 17B). However, the amount of GMs and the 
concentration of FITC-dextran were constant for both static and perfusion, and we 
were able to conclude that much more released FITC-dextran was collected in static 
than in perfusion. Therefore, a large amount of released FITC-dextran remains in the 
3D-μFCCS as opposed to static situations. This study could to an extent prove the 
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Figure 17: a comparison of the amount of released molecules between static and perfusion 
conditions (A) Under perfusion conditions, the GMs loaded with 70 KDa of FITC-dextran 
was immobilized behind the micropillars in the 3D-µFCCS, with 1×PBS perfused at 0.05 
ml/h. (B) The fluorescence intensity of PBS collected under both static and perfusion 
conditions was measured. Data are mean ± S.E.M. of 3 independent experiments. 
 
4.3.6 Seeding of GMs with cells into the 3D-µFCCS 
To create a soluble microenvironment for the cells to be cultured in the 3D-µFCCS, 
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GMs has to be trapped together with the cells in the 3D-µFCCS to release the soluble 
factors which are critical components in the soluble microenvironment. The average 
size of the GMs is much bigger than that of the cells and the GMs are more rigid and 
heavier than the cells. Therefore, seeding the GMs into the 3D-µFCCS is often 
coupled with technical problems, i.e. GMs tend to sink and stick to the bottom of the 
cell culture compartment instead of flowing and getting inter-dispersed with cells, or 
they tend to block the entrance of the cell culture compartment because they are 
relatively bigger. 
 
To efficiently solve the technical problems, the cell/GM ratio has to be optimized for 
seeding. Empirically, we found that a density of 8~12 million cells/ml can result in 
efficient seeding and packing of cells in the 3D-µFCCS. Based on this experience, the 
density of GMs was further optimized. We mixed ~2000, ~6000 and ~12000 GMs 
with the cell suspension thoroughly and introduced the mixture into the cell reservoir 
for seeding. At the end of seeding, we found that ~2000 and ~6000 GMs did not cause 
any blocking of the entrance, and ~6000 GMs resulted in more entrapment of GMs in 
the cell culture compartment as compared to 2000 GMs (Fig. 18A and 18B, indicated 
by black arrows). ~12000 GMs, on the other hand, caused severe clogging in the 
3D-µFCCS and seeding was not successful (Fig. 18C). Therefore, we concluded that 
by controlling the cell/GM ratio, the number of GMs trapped in the 3D-µFCCS can be 





Figure 18: seeding of cell/GM mixture in the 3D-µFCCS (A) 2000 GMs in the cell suspension 
for seeding resulted in less immobilized GMs in the cell culture compartment as compared to 
(B) 6000 GMs. On the other hand, (C) 12000 GMs in the cell suspension caused severe 
clogging (GMs are indicated by black arrows). 
 
4.3.7 Characterization of the soluble microenvironment in the 3D-µFCCS  
Previous studies on the 3D-µFCCS have shown that the flow adjacent to the 
micropillar array was only via diffusion and the rate was almost zero.158, 159 Therefore 
we hypothesized that the micropillar array in the 3D-µFCCS can serve as a barrier to 
keep the soluble microenvironment undisrupted by fluid flow and keep localized in 
the cell culture compartment. To test this hypothesis and to visualize and characterize 
the soluble microenvironment in the 3D-µFCCS, we attempted to use the imaging 
method for qualitative and quantitative studies. GMs loaded with 70 KDa 
FITC-dextran were seeded in the cell culture compartment in the 3D-µFCCS. Fluid 
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flow at 0.05 ml/h was applied after seeding for 4 days. Images were taken every 30 
minutes for quantification. We measured the fluorescence intensity across the width 
of the 3D-µFCCS (Fig. 19A, indicated by the white dashed line) to evaluate whether 
fluid flow would impact the soluble microenvironment. The profile of the 
fluorescence intensity inside the 3D-µFCCS was plotted. A huge peak at the center 
with a width of ~ 200µm was observed (Fig. 19C), indicating that the soluble 
microenvironment was defined by the micropillar array. However, the height of the 
peak gradually reduced during 4 days (Fig. 19C, from the red lines to the pink lines), 
which could be due to both photo-bleaching (Fig 19A and 19B) and release of 
FITC-dextran. Therefore, no conclusion as to whether the soluble microenvironment 
was undisrupted and localized in the cell culture compartment could be drawn.  
 
We redesigned the experiment by introducing a mixture of cells and Rhodamine B 
isothiocyanate (RITC)-dextran-loaded-GMs into the 3D-µFCCS, with the GM 
distribution being very sparse (~50 GMs per channel) (Fig. 20A). This is because 
RITC still allows optical interrogation (Fig. 20B) but is not as easily photo-bleached 
as FITC, and “GMs inter-dispersed with cells” is a realistic simulation to subsequent 
cell culture. Four different flow rates were applied to the 3D-µFCCS. A plot of the 
normalized fluorescence across the centre channel is given in Fig. 20C. These values 
were calculated at a distance away from the GM center (the white dashed line shown 
in Fig. 20B) such that maximum intensity is 1/15 of the intensity at the centre of the 
GM. Even with no flow applied, the fluorescence within the side channels is 
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significantly lower than that in the centre channel. When different flow rates were 
applied, the intensity of the fluorescence at the side channels almost remained 
constant and still significantly lower, suggesting that flow rate did not have any 
significant impact on the molecules released from GMs, and the released molecules 
was indeed largely confined to the center channel. With an average density of 50 GMs 
per channel, the resultant GM spacing will approximately be 200 µm from each other, 
resulting in a fairly even distribution of soluble factors within the centre channel and 
still minimum leakage into the side channels. This study confirmed that it is possible 
to use GMs for creating an undisrupted and localized soluble microenvironment 




Figure 19: characterization of the concentration profile of the soluble microenvironment in the 
3D-µFCCS. (A) GMs loaded with FITC-dextran were immobilized behind the micropillars in 
the 3D-µFCCS with fluid perfusion at 0.05 ml/h. Concentration represented by fluorescence 
intensity across the 3D-µFCCS can be measured (white dashed line). (B) However, 
FITC-dextran are severely photo-bleached after 4 days and (C) the plotted fluorescence 









Figure 20: characterization of concentration profile in the multi-channel 3D-μFCCS (A) We 
seeded cells and RITC-dextran-loaded-GMs into the multi-channel 3D-µFCCS, and the GMs 
were inter-dispersed with cells as shown in the transmission image. (B) RITC-dextran is 
fluorescent and allows optical interrogation. (C) Four different flow rates (0, 0.05, 0.1 and 0.2 
ml/h) were applied and a plot of the normalized fluorescence across the central channel is 





We have observed that flow rates at a low level did not have any significant impact on 
the distribution pattern of the molecules inside the 3D-μFCCS (Fig. 20C), possibly 
due to the nature of laminar flow inside microfluidic devices.15, 160 In principle, the 
laminar flow at the two side channels will not disrupt the environment in the central 
channel while the mass transfer between the central and two side channels is 
diffusion-driven. This relatively constant soluble microenvironment can potentially 




We optimized the design of the 3D-µFCCS for more constant fluid flow and 
minimized bubble formation. The versatility of the 3D-µFCCS was further validated 
by culturing various cell types originated from different species and organs. Meawhile, 
the conditions for GM fabrication was optimized by evaluation of GM morphology as 
well as measurement of their controlled-release properties. The GMs were able to 
controlled-release molecules with different molecular weight and they can be 
immobilized together with cells in the 3D-µFCCS, given proper GM/cell ratios. The 
soluble microenvironment composed of the molecules released from GMs in the 
3D-µFCCS was characterized under fluid flow. Results indicated that a relative 
constant soluble microenvironment was localized in the central cell culture 
compartment, regardless of the fluid flow rate. Therefore, we conclude that 
controlled-release of molecules can facilitate the creation of a soluble 
microenvironment in the 3D-µFCCS. 
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CHAPTER 5 Engineering the Soluble Microenvironment in the 3D-µFCCS for 
Functional Enhancement of Primary Rat Hepatocytes 
5.1 Introduction 
Liver tissue engineering applications such as testing of drugs,149 pathogens 161, 162 or 
other xenobiotics,163 and the development of implantable liver tissues 150, 151 or 
extra-corporeal liver-assisted devices 164 require in vitro cultured hepatocytes that can 
maintain high levels of metabolic functions over a prolonged period of time.165, 166 
Recently, we have developed a 3D-µFCCS to recapitulate the in vivo environmental 
cues to support high levels of liver-specific functions in vitro.17 One particular 
environmental cue that the 3D-μFCCS tries to recapitulate is the microcirculation of 
the liver sinusoids in vivo allowing effective supply of nutrients to and removal of 
metabolic wastes from the hepatocytes, which are very sensitive to the shear stress 
and normally protected by the sinusoidal endothelial cells aligning the liver 
sinusoids.167 The 3D-µFCCS has been optimized for cellular support with efficient 
mass transfer, shear stress reduction and can be employed in hepatotoxicity testing of 
drugs.86 
 
The key to constructing an in vitro model to reliably predict the in vivo drug responses 
as means to eliminate false lead candidates early in the drug development process is to 
ensure that the cultured hepatocytes exhibit high levels of metabolic functions closely 
matching those measured in vivo. Previous studies have found co-cultures of 
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hepatocytes with supporting cells in various culture systems, e.g. 2D monolayer,168 
3D hepatocyte spheroids,169 micropatterned surfaces,66 to exhibit the desired level of 
hepatocyte functions in vitro. Unfortunately, establishing co-cultures in microfluidic 
systems can be challenging: hepatocytes and fibroblasts exhibit very different 
physical and biological characteristics in microfludic systems, creating operational 
complexity, such as non-uniform distributions during cell seeding, different cell 
proliferation rates and culture requirements of the two cell types, as well as potential 
interference of hepatotoxicity results due to the presence and metabolic activities of 
the supporting fibroblasts.170 
 
To avoid such operational complexity, we exploited our mechanistic understandings 
that low levels of TGF-β1 secreted by fibroblasts can enhance hepatocyte functions in 
co-cultures.153 To mimic the “co-culture effect” in the 3D-μFCCS without culturing 
fibroblasts, TGF-β1 can be presented to the hepatocytes by in situ controlled-release 
from the local microenvironment utilizing GMs. The soluble microenvironment 
composed of TGF-β1 was therefore established. TGF-β1 is a bioactive molecule with 
a very short half-life of only a few minutes in aqueous environment20 but can be 
preserved from inactivation by encapsulation in controlled-release carriers, hence 
extending the TGF-β1 activities for up to 1 week.21 We report here that the method of 
controlled-release of TGF-β1 can maintain high levels of hepatocyte functions 
without the complications of co-cultures in 3D-μFCCS, simplifying drug testing 
applications. Such an alternative solution to the general problem of co-culturing cells 
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in microfluidics can also be adopted in other hepatocyte-based applications at larger 
scales, such as bio-artificial liver-assist devices. 
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5.2 Materials and Methods 
5.2.1 Assessment of the size distribution of the GMs 
The GM samples were placed on a glass slide and visualized under a light microscope 
(Carl Zeiss SV6, Germany). 25 images of the GMs were taken for image analysis. The 
size of the GMs was determined by ImagePro® Plus (Media Cybernetics, USA)  
 
5.2.2 Scanning electron microscopy (SEM) 
GMs were suspended in DI water and 10 ml of the suspension was placed on a 
poly-lysine coated glass slide, air dried, dehydrated and then platinum sputtered (20 
mA, 60 s) before viewing with a field emission scanning electron microscope (JEOL, 
Japan). 
 
5.2.3 Characterization of TGF-β1 release profile from the GMs 
The amount of TGF-β1 released from the gelatin microspheres was assessed by a 
TGF-β1 ELISA kit (Promega, USA) according to the manufacturer’s protocol. 
TGF-β1 was dissolved in 2% BSA solution (PeproTech Inc, USA). To load the GMs, 
1 mg of GMs was soaked in 0.5 ml TGF-β1 solution at 4 ºC overnight. The 
entrapment efficiency was less than 50%. To determine the release profile under 
dynamic conditions, the TGF-β1-loaded GMs were introduced into the 3D-μFCCS 
and were immobilized by the micropillars. 2% BSA was perfused continuously at 0.05 
ml/h through the 3D-μFCCS for 7 days. 1.2 ml perfusate was collected daily to 
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quantify TGF-β1 concentration.  
 
5.2.4 Estimation of the concentration of in situ controlled-released TGF-β1 in the 
3D-μFCCS 
We aimed to controlled-release 100-200 pg/ml of TGF-β1 in the 3D-μFCCS. To 
obtain the final expected concentration of TGF-β1 in the centre cell culture 
compartment, we calculated the number of TGF-β1-loaded GMs in the 3D-μFCCS. 
We can measure the TGF-β1 concentration from the perfusate. To estimate the number 
of GMs required achieving a desired final concentration, the equation for calculation 
is as follows: 
( . 1) . . 3 3
.  
1 .
desired conc of TGF max No of GMs in D FCCS volume of D FCCS
No of GMs required
measured TGF conc volume of perfusate
β μ μ
β
   − ×     − ×  − =  
 − ×   
 
The number of GMs in the 3D-μFCCS is ~10000; the volume of the cell culture 
compartment in the 3D-μFCCS is 0.00006 ml; and the volume of the perfusate is 1.2 
ml. 
 
5.2.5 Primary rat hepatocyte isolation 
Hepatocytes were harvested from male Wistar rats weighing from 250 to 300 g by a 
two-step in situ collagenase perfusion method.171 Hepatocytes used in all experiments 
had a cell viability of >90%, as determined by Trypan Blue exclusion assay, and a 
yield of 200–300 million cells. 
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5.2.6 Hepatocyte seeding and culture in the 3D-μFCCS 
3 million hepatocytes and 3000-9000 GMs were resuspended in 1 ml of methylated 
collagen solution. To immobilize the hepatocyte/GM mixture in the 3D-μFCCS, the 
hepatocyte/GM suspension was withdrawn from the cell reservoir, via the outlet, 
using a withdrawal syringe pump (Cole-Parmer, USA). Laminar flow complex 
coacervation was implemented as described previously17, followed by infusing culture 
medium for displacing excess polyelectrolytes. Hepatocytes were cultured on a heater 
plate (MEDAX, Germany) at 37 ºC, with medium perfused continuously at 0.05 ml/h. 
The perfusate was collected daily for functional assessment.  
 
5.2.7 Qualitative assessment of the GM distribution in the 3D-μFCCS 
The GMs were fluorescently labeled by soaking them in 0.05% Rodamine-Dextran 
(Sigma, USA) at 4 ºC overnight and were then mixed with hepatocytes. The mixture 
was immobilized in the 3D-μFCCS according to section 2.9. The hepatocytes were 
stained with Calcein AM (Molecular Probes, USA) as previously described.17 The 
cell/GM containing 3D-µFCCS was then imaged using a confocal microscope 
(Olympus Fluoview, Japan).  
 
5.2.8 Functional assessment of hepatocytes 
All functional data were normalized to cell number (DNA content) quantified using 
PicoGreen assay (Molecular Probes, USA) according to the manufacturer’s protocol. 
Albumin production was assessed by measuring albumin concentration in the 
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collected perfusate quantified with a rat albumin ELISA quantification kit (Bethyl 
Laboratories Inc, USA). Albumin production is expressed as the total albumin (μg) 
collected in culture medium per million cells over 24 hours. 
UDP-glucuronyltransferase (UGT) and CYP450 activity of the hepatocytes cultured 
in the 3D-μFCCS were determined by infusing 100 mM  4-methylumbelliferone 
(4-MU) and 50 µM 3-cyano-7-ethoxycoumarin (CEC) (Sigma, USA), respectively, 
for 4 hours at 0.2 ml/h. The perfusate (800 µl) was collected and the amount of the 
metabolic products, 4-methylumbelliferyl glucuronide (4-MUG) and 
3-cyano-7-hydroxycoumarin (CHC) were analyzed using capillary electrophoresis 
with laser induced fluorescence (CE-LIF) detection (Prince Technologies B.V., 
Netherlands) at an excitation wavelength of 325 nm 17. 4-MUG and CHC production 
are expressed as total amount of 4-MUG (μg) and CHC (μg) collected in culture 
medium per million cells over 4 hours.  
 
5.2.9 Hepatotoxicity testing in the 3D-μFCCS 
Acetaminophen (APAP) was used as a model drug to perform hepatotoxicity testing. 
APAP dosing at 20 mM and 40 mM commenced 72 hours after seeding hepatocytes 
into the 3D-μFCCS. Hepatotoxicity was examined after 24 hours of drug dosing by 
quantifying cell viability as a cytotoxicity endpoint (determined by a co-staining 
method): two fluorescent nuclear dyes i.e. Propidium iodide (PI) (Molecular Probes, 
USA) and Hoechst 33342 (Molecular Probes, USA) were used to selectively stain the 
necrotic and total cell population. The staining was effected by perfusing the mixture 
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of the reagents at a flow rate of 0.05 ml/h for 50 minutes. The concentrations of the 
two dyes were 25 μg/ml (PI) and 5 μg/ml (Hoechst 33342), respectively. The cells 
were then fixed by perfusing 3.7% Paraformaldehyde (PFA) for 30 minutes. All 
stained samples were imaged with a confocal microscope (Olympus Fluoview, Japan) 
at 543 nm and 405 nm excitation. For each 3D-μFCCS, a 100 μm optical section (with 
2 μm step size) was acquired at 4 sites along the length of the channel. A 3D stack was 
obtained and the number of objects for both red (dead cells) and blue (total cells) 
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5.3 Results and discussions 
To mimic the role of supporting cells in co-cultures, we presented 100-200 pg/ml 
TGF-β1 by in situ controlled-release from GMs inter-dispersed with the primary 
hepatocytes immobilized in the 3D-μFCCS. We compared the effects of in situ 
controlled-release of TGF-β1 from the GMs to direct perfusion of TGF-β1 on 
hepatocyte functions and drug-mediated hepatotoxicity.  
 
5.3.1 Incorporating TGF-β1 loaded GMs into the 3D-μFCCS 
The 3D-μFCCS consists of a micropillar array which divides the microfluidic channel 
into a centre compartment for cell culture and two side channels for perfusion of 
culture medium (Fig. 21A). The centre compartment is connected to a cell reservoir 
from which cells can be introduced into the 3D-μFCCS. The micropillar array allows 
the TGF-β1 loaded GMs and hepatocytes to be physically immobilized within the 
centre compartment. 
 
During cell seeding, we introduced the GM/hepatocyte mixture into the cell reservoir 
and applied a withdrawal flow rate of 0.02-0.03 ml/h at the outlet (Fig. 21A). To 
effectively immobilize hepatocytes and GMs in the 3D-μFCCS without causing 
clogging, a suspension of 1.5 million hepatocytes and 3000-9000 GMs in 500 µl 
methylated collagen was found to be optimal, leading to the entrapment of ~5000 
hepatocytes and 10-30 GMs, as determined by imaging and PicoGreen assay. We 
investigated the GM distribution in the 3D-μFCCS by fluorescently labeling 
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hepatocytes with Calcein-AM (grey) and GMs with Rhodamine-Dextran (yellow). 
Images were taken at different locations along the length of the 3D-µFCCS (Fig. 21B) 
which showed qualitatively uniform GM distributions. 
 
We quantified the size distributions and the controlled-release property of the GMs in 
3D-μFCCS. The size distribution was characterized by analyzing the images acquired 
using phase-contrast microscopy (Fig. 21B and 22A). The insert of Fig. 22A is an 
SEM image of the typical GMs with smooth surfaces and size distribution. The size 
distribution of the GMs (21±7 μm in diameter) is comparable to that of the fabricated 
GM samples (14±6µm in diameter). The controlled-release property of the GMs in the 
3D-µFCCS was evaluated under dynamic flow of 0.05 ml/h. In this study, the primary 
hepatocytes were cultured for 7 days. Therefore the controlled-release of TGF-β1 
from the GMs was evaluated for 7 days. GMs can be preserved in aqueous solution 
for at least up to four weeks if studies on long-term controlled-release are needed. The 
3D-µFCCS was fully packed with TGF-β1-loaded-GMs (~10000 GMs/channel) and 
the total amount of the released TGF-β1 showed a linear increase from 47±7 pg to 
474±82 pg over 7 days, with an average daily release of 71±14 pg (Fig. 22B). Thus, 
~10000 GMs released a total amount of ~71 pg TGF-β1 everyday and according to 
the formula in section 2.7, the number of GMs to be immobilized in the 3D-µFCCS 
was calculated to be 10, 20 and 30 to release TGF-β1 at the concentrations of 100, 
200 and 300 pg/ml, respectively. 
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Figure 21: primary hepatocytes and gelatin microspheres (GMs) in the 3D-μFCCS (A) 
schematic representation of the seeding process of primary hepatocytes mixed with GMs; (B) 
confocal images of the immobilized mixture of primary hepatocytes (grey) and GMs (yellow) 
in the 3D-μFCCS (top panel). Images were taken at three different sites, near the entrance of 
the cell culture compartment, centre of the cell culture compartment and near the exit of the 






Figure 22: characterization of the fabricated GMs. (A) Size distribution of the GMs seeded in 
the 3D-μFCCS as compared to those fabricated samples. Insert: SEM image showing the 
representative size of the GMs (scale bar: 10μm). (B) Measurement of the controlled release 
profile of TGF-β1 from the GMs in the 3D-μFCCS under dynamic flow for 7 days. Data are 
the mean ± s.e.m. of 3 independent experiments.  
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5.3.2 Determining the optimal TGF-β1 concentration for primary hepatocytes in 
3D-µFCCS  
We compared the effect of directly perfused TGF-β1 to in situ controlled-released 
TGF-β1 on the levels of albumin secretion by the hepatocytes in the 3D-µFCCS. 
Three concentrations, 100 pg/ml, 200 pg/ml and 300 pg/ml, were directly perfused. 
When 200 pg/ml of TGF-β1 was directly perfused to the hepatocytes, albumin 
secretion showed a significantly higher level (98 ±15 µg on day 3, 40±9 µg on day 5 
and 11±1 µg on day 7) as compared to that stimulated by 100 pg/ml (8±1 µg on day 3, 
5±3 µg on day 5, and 5±1 µg on day 7) or 300 pg/ml of TGF-β1 (7±4 µg on day 3, 
5±2 µg on day 5 and 4±3 µg on day 7) (Fig. 23A).  
 
To in situ controlled-release TGF-β1 at the concentrations of 100, 200 or 300 pg/ml, 
the number of GMs immobilized in the 3D-µFCCS was estimated to be 10, 20 or 30 
(see section 2.7). We observed that by suspending a mixture of 1.5 million 
hepatocytes with 3000, 6000 or 9000 GMs in 500 µl methylated collagen will give 
rise to the entrapment of ~5000 hepatocytes with 9±4, 17±3 or 32±7 GMs respectively; 
yielding a final concentration of 100-110 pg/ml, 200-220 pg/ml or 300-320 pg/ml of 
TGF-β1 released. With in situ controlled-release, the concentration of 200-220 pg/ml 
was the most efficient in enhancing albumin secretion (69±19 µg on day 3, 51±2 µg 
on day 5 and 47±9 µg on day 7) as compared to 100-110 pg/ml (28±5 µg on day 3, 
27±7 µg on day 5 and 6±5 µg on day 7) or 300-320 pg/ml (12±4 µg on day 3, 2±1 µg 
on day 5 and 1±0.3 µg on day 7) (Fig. 23B). Unlike direct perfusion of 200 pg/ml of 
TGF-β1 which led to rapid decrease in albumin secretion, in situ controlled-release of 
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TGF-β1 at 200-220 pg/ml maintained albumin secretion at ~50 µg from day 5 to 7. 
These results led us to choose 200-220 pg/ml of TGF-β1 as the concentration for 
optimal hepatocytes functions in the 3D-μFCCS and the in situ controlled-release 
feature retarded the decline in albumin secretion. 
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Figure 23: determination of the optimal concentration of controlled presented TGF-β1 for 
primary hepatocytes in the 3D-µFCCS by evaluation of albumin secretion for 7 days. (A) 
Optimization for directly perfused TGF-β1 (  100 pg/ml;  200 pg/ml;  300 pg/ml). (B) 
Optimization for in situ controlled-released TGF-β1 (  100-110 pg/ml;  200-220 pg/ml; 
 300-320 pg/ml). Data are the mean ± s.e.m. of 2 independent experiments, **: p<0.05, *: 
p<0.1 
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5.3.3 Assessment of metabolic enzyme activities of hepatocytes in 3D-µFCCS 
We compared the metabolic functions of the primary hepatocytes cultured without or 
with TGF-β1, directly perfused or in situ controlled-released from GMs in the 
3D-µFCCS, i.e. CYP450 enzymatic (phase І metabolic enzyme) activity and UGT 
enzymatic (phase II metabolic enzyme) activity. When TGF-β1 was presented to the 
hepatocytes, the CYP450 enzymatic activity was stimulated (144±27/106±3 μg on 
day 3, 122±23/105±21 μg on day 5, 186±36/94±9 μg on day 7 for in situ 
controlled-release/direct perfusion of TGF-β1) compared to the control without 
TGF-β1 (99±15 μg on day 3, 57±14 μg on day 5 and 72±6 μg on day 7). Furthermore, 
in situ controlled-release of TGF-β1 from GMs in 3D-μFCCS resulted in significantly 
higher CYP450 enzymatic activity than the directly perfused TGF-β1 (144±27 vs. 
106±3 μg on day 3, 122±23 vs. 105±21 μg on day 5 and 186±36 vs. 94±9 μg on day 7) 
(Fig. 24A).  
 
We observed similar trend in the UGT enzymatic activity assessment. The UGT 
enzymatic activity of hepatocytes presented with TGF-β1 was significantly higher 
(3558±585/1904±202 μg on day 3, 3253±1244/1008±64 μg on day 5, 
1265±675/535±288 μg on day 7 for in situ controlled-release/direct perfusion of 
TGF-β1) than the control without TGF-β1 (1422±463 μg on day 3, 1156±643 μg on 
day 5, and 216±204 μg on day 7). The enhancement of UGT enzymatic activities in 
hepatocytes presented with in situ controlled-release of TGF-β1 was at least two-fold 
higher than achieved by direct TGF-β1 perfusion (3558±585 vs. 1904±202 μg on day 
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3, 3253±1244 vs. 1008±64 μg on day 5 and 1265±675 vs. 535±288 μg on day 7) (Fig. 
24B). On day 7, the overall UGT enzymatic activity of the hepatocytes declined even 
though the phase I metabolic activity was maintained.  
 
5.3.4 Improved drug sensitivity of hepatocytes with controlled TGF-β1 
presentation in 3D-µFCCS 
We compared the sensitivities of the hepatocytes to APAP in the 3D-μFCCS, cultured 
without or with TGF-β1, directly perfused or in situ controlled-released from GMs in 
the 3D-µFCCS. After exposure to 20 mM and 40 mM of APAP for 24 hours, the 
hepatocytes were assessed for viability using fluorescent labeling. The percentage of 
viable cells was quantified using image processing (Fig. 25). At 20 mM APAP, when 
TGF-β1 was presented to the hepatocytes, the drug-mediated sensitivity was higher 
(41±4% viability for in situ controlled-release and 57±17% viability for direct 
perfusion of TGF-β1) than the control without TGF-β1 (70±14% viability). 
Furthermore, in situ controlled-release of TGF-β1 from GMs in 3D-μFCCS resulted 
in significantly higher sensitivity than the directly perfused TGF-β1 (41±4% viability 
vs. 57±17% viability)  
 
The same trend was observed when APAP concentration was increased to 40 mM. The 
drug-mediated sensitivity of hepatocytes presented with TGF-β1 was higher (24±7% 
viability and 38±8% viability for in situ controlled-release and direct perfusion of 
TGF-β1) than the control without TGF-β1 (43±8% viability). In situ 
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controlled-release of TGF-β1 from GMs in 3D-μFCCS resulted in significantly higher 
sensitivity than the directly perfused TGF-β1 (24±7% viability vs. 38±8% viability) 




Figure 24: assessment of metabolic activity of the primary hepatocytes for 7 days (  normal 
culture medium for hepatocyte culture without TGF-β1;  200 pg/ml TGF-β1 via directly 
perfused;  200-220 pg/ml TGF-β1 via in situ controlled released). (A) CHC production, as 
a measure of phase 1 CYP 450 metabolic enzyme activity. (B) 4-MUG production, as a 
measure of phase 2 UGT enzyme activity. Data are the mean ± s.e.m. of 2 independent 




Figure 25: assessment of the drug mediated hepatotoxicity of primary hepatocytes  normal 
culture medium for hepatocyte culture without TGF-β1;  200 pg/ml TGF-β1 via directly 
perfused;  200-220 pg/ml TGF-β1 via in situ controlled released). Data are the mean ± 
s.e.m. of 2 independent experiments, **: p<0.05, *: p<0.1 
 
Liver-tissue engineering applications require hepatocytes cultured in vitro to maintain 
high levels of metabolic functions.165, 166 Co-cultures with fibroblasts can efficiently 
stimulate and maintain hepatocyte functions 65, 172 (e.g. 5 times higher of albumin 
secretion level and 6 times higher of detoxifying activity than mono-culture) due to 
the soluble factors secreted by the supporting cells. However, co-culture support of 
hepatocyte functions occurs only when the fibroblasts are proliferating.173 
Hepatocytes in 3D-µFCCS exhibited enhanced functions; unfortunately, due to 
limited space inside a microfluidic device and loss of a fixed ratio of cells, it is 
challenging to co-culture non-proliferating hepatocytes with proliferative fibroblasts. 
We resolved this dilemma by stimulating hepatocyte functions in the 3D-µFCCS 
through controlled-release of TGF-β1 so that a soluble microenvironment composed 
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of TGF-β1 was created to support hepatocyte functions. 
 
The 3D-µFCCS was developed to recapitulate the in vivo environmental signals to 
support liver-specific functions in vitro.17 Based on the 3D-µFCCS, the soluble factor 
TGF-β1 which was previously reported to be primarily responsible for the high levels 
of hepatocyte functions observed in hepatocyte-fibroblast co-cultures,153 was 
controlled-released to the hepatocytes. In the presence of 200-220 pg/ml TGF-β1, 
albumin secretion and phase I/II metabolic enzymatic activities of the hepatocytes in 
the 3D-μFCCS was significantly enhanced compared to the control without TGF-β1.  
This provides the proof-of-concept support to the hypothesis that the presence of 
TGF-β1 can enhance hepatocyte functions in a microfluidic platform, even surpassing 
the level achieved with hepatocyte-fibroblast co-cultures.174, 175 
 
Compared to the direct perfusion of TGF-β1, the in situ controlled-release of TGF-β1 
by means of GMs facilitated further functional enhancement of 4.5, 2 and 3 folds 
more in albumin secretion, phase I and phase II activities respectively. This functional 
enhancement is primarily due to the creation of a constant soluble microenvironment 
composed of TGF-β1, whereby maintenance of hepatocyte functions was achieved. 
Also, preservation of the TGF-β1 bioactivity in the GMs was another explanation as 
to how the hepatocyte functions were enhanced. Moreover, hepatocytes might be in 
close or direct contact with the GMs in the 3D-µFCCS, together with the micro- or 
nanoscale-featured contacting surfaces that increased the cells’ capability of 
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perception,176 leading to more active TGF-β1 uptake. With the enhanced enzymatic 
activities in TGF-β1, hepatocytes in 3D-µFCCS exhibited higher sensitivity to APAP 
induced cytotoxicity compared to the control without TGF-β1. 20 mM of APAP 
induced ~50% of cell death in 200-220 pg/ml TGF-β1 in the 3D-μFCCS compared to 
the control without TGF-β1, which required 40 mM of APAP (Fig. 25). TGF-β1 itself 
did not directly cause hepatoxicity as the hepatocytes exhibited no loss of cell 
functions in TGF-β1 without APAP (Fig. 24). 
 
There are many other hepatocyte-based applications such as the disease models for 
therapy (e.g. proteolytic enzyme therapy for liver cancer treatment 177), pathogen 
testing (e.g. pathogen identification for hepatitis B 104) and bioreactors for the 
development of the bio-artifical liver device (BLAD). Hepatocyte co-cultures have 
been proposed 178 and developed 179 as an attractive way to enhance hepatocyte 
functions and system performances. However, the optimized ratio of hepatocytes to 
the supporting co-cultured cells is critical for efficient cell-cell interactions and thus 
the functional maintenance of hepatocytes.65 Such operational complexity of 
co-culturing hepatocytes and supporting cells at a precise ratio can be avoided by 
replacing the supporting cells with the in situ controlled-release of TGF-β1.  
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5.4 Conclusion  
We have developed a strategy to replace hepatocyte-fibroblast co-cultures for 
maintaining high levels of hepatocyte functions in 3D-µFCCS. This was achieved by 
creating a soluble microenvironment to favor in vitro culture of hepatocytes. TGF-β1 
was controlled-released to the immobilized hepatocytes in 3D-µFCCS, as a major 
component in the soluble microenvironment. 200-220 pg/ml of controlled-released 
TGF-β1 resulted in higher hepatocyte functions (albumin secretion, phase I and phase 
II metabolic enzyme activities) compared to directly-perfused TGF-β1 or the control 
without TGF-β1. The measured hepatocyte sensitivity to APAP induced cytotoxicity in 
our 3D-µFCCS with in situ controlled-released TGF-β1 approaches that of the in vivo 
drug-induced hepatotoxicity.  
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CHAPTER 6 Culturing Multiple Cell Types on a Multi-Channel 3D-μFCCS 
with Compartmentalized Microenvironments 
6.1 Introduction 
In the early phase of drug development, the only way to obtain in vivo data to predict 
the pharmacokinetic responses from human is the use of animal models.154 
Experiments on animals are, however, expensive, lengthy and controversial.18 There 
are also concerns whether data from animal tests can be applied to humans due to 
deficiency in cross-species extrapolation.180, 181 Therefore, affordable alternative in 
vitro models are needed to more closely mimic the human situation in vivo.  
 
Microscale systems are well suited for the development of these in vitro models due to 
their compact sizes, their multiplexing capability,81, 160 and their ability to recapitulate 
a controllable microenvironment at the cellular level.80 Various microscale 
“animal-on-chip” or “human-on-chip” cell culture systems have been developed, such 
as liver cells on chip for hepatotoxicity testing,116 in vitro microfluidic system for 
culturing sperm cells,182 cell culture chips that mimic the vascular system,183 and 
microfluidic chips that maintain and stimulate brain tissues.184, 185 In particular, Shuler 
et al. developed an integrated μCCA specifically for pharmacokinetic studies.106 It 
was designed on the basis of a simplified mathematical representation of the body as 
several interconnected compartments with specific flow parameters. The μCCA 
contained drug-metabolizing liver and lung cells, as well as fat cells which act as a 
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storage reservoir for lipophilic compounds. Cells were cultured in a 2D 
fluidically-linked fashion with culture medium circulated as a blood surrogate; the 
systemic effect of a drug on the cells was then evaluated. The development of the 
μCCA laid the foundation for a realistic in vitro pharmacokinetic model and provided 
an integrated biomimetic system for culturing multiple cell types with high fidelity to 
in vivo situations. 
 
When the cells are cultured in a fluidically-linked fashion, the medium can efficiently 
provide nutrients to and remove wastes from the cells.186 However, the perfusate 
which contains many unknown wastes from previous compartments is likely to be 
toxic to the cells in the following compartments.96 Such toxic effect may amplify 
when culture medium is being circulated for several days. However, in humans, blood 
facilitates waste removal as it is pumped through every organ. Since the 
microcirculation in organs is based on diffusion, thus wastes from organs enter 
bloodstream in a diffusion-controlled manner.187, 188 Therefore, very limited amounts 
of toxic factors will be brought forward to the next organ, which is relatively isolated 
from the others. Therefore, to engineer a system with high fidelity to in vivo situations, 
it is important to culture multiple cell types in a fluidically-linked fashion while 
maintaining their compartmental isolation from one another, a major shortcoming 
which the μCCA failed to address. 
 
Our group has previously developed a 3D-μFCCS with a central micropillar array.17 
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Cells were immobilized behind the micropillars and medium was perfused from the 
two flanking channels (side channels). As there is no flow through the central channel, 
mass transfer between medium and cells is by diffusion only, resembling the in vivo 
situations. Inside such a cell culture compartment, we have demonstrated controlled 
release of specific growth factors from GMs, thus limiting the leakage of growth 
factors during perfusion.189 In this study, we multiplexed the 3D-μFCCS into a 
four-compartment chip for culturing four different human cell types: C3A (liver), 
A549 (lung), HK-2 (kidney), and HPA (fat), to represent the drug-metabolizing and 
storage capabilities in the human body. A common basal culture medium was 
optimized for enhancing the functions of all cell types. In addition to the common 
basal medium, we found that TGF-β1 enhanced the functions of A549 and HPA but 
inhibited the functions of C3A. Thus, we specifically controlled-released TGF-β1 
from GMs inside the A549 compartment during cell culture. It was found that the 
function of A549 cells was enhanced while the functions of C3A, HK-2 and HPA cells 
were uncompromised, demonstrating compartmental isolation between different cell 
types. Such a system (hereafter referred to as multi-channel 3D-μFCCS) can be used 
to simultaneously culture multiple cell types and optimize their cellular functions for 





6.2 Materials and methods 
6.2.1 Cell maintenance 
All cell culture components are purchased from GIBCO, Invitrogen, USA unless 
otherwise stated. A549, HK-2 (ATCC, USA) and primary human preadipocyte (HPA) 
(PromoCell) were cultured in DMEM/F12-K (1:1) supplemented with 10% fetal 
bovine serum, 1.5 g/L sodium bicarbonate, 1 mM L-glutamine, 100 units/ml penicillin 
and 100 g/ml streptomycin. C3A (ATCC, USA) was cultured in MEM supplemented 
with 10% fetal bovine serum, 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 
100 units/ml penicillin and 100 g/ml streptomycin. To induce HPA to matured 
adipocytes, the culture medium was replaced with differentiation medium (PromoCell, 
Germany) and the HPA was maintained in differentiation medium for 3 days to ensure 
complete maturation. 
 
6.2.2 Cell seeding and culture in the multi-channel 3D-μFCCS 
The four cell types were immobilized in the multi-channel 3D-μFCCS one by one 
similar as previously described.189 To immobilize the A549/GM mixture in the 
multi-channel 3D-μFCCS, 12 million A549 and 9000 GMs were suspended in 0.5 ml 
of methylated collagen. The A549/GM suspension was withdrawn from its 
corresponding cell reservoir, via the outlet, using a withdrawal syringe pump 
(Cole-Parmer, USA). 9 million C3A, 10 million of HK-2 and 6 million of HPA were 
also suspended in 0.5 ml of methylated collagen in three different 1.5 ml tubes 
(Eppendorf, Germany) and withdrawn from their corresponding cell reservoir one by 
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one. Laminar flow complex coacervation was implemented as described previously.17 
Cells were cultured on a heater plate (MEDAX, Germany) at 37 ºC, with a common 
medium perfused continuously at 0.2 ml/h. Their perfusate can be collected 
individually for functional assessment. 
 
6.2.3 Characterization of TGF-β1 release profile from the GMs 
The amount of TGF-β1 released from the gelatin microspheres was assessed by a 
TGF-β1 ELISA kit (Promega, USA) according to the manufacturer’s protocol similar 
as previously described in section 5.2.3. To load the GMs, 6 mg of GMs was soaked 
in 0.5 ml of 500 ng/ml TGF-β1 solution at 4 ºC overnight. To determine the release 
profile under dynamic conditions, the TGF-β1-loaded GMs were introduced into the 
lung compartment of the multi-channel 3D-μFCCS and were immobilized by the 
micropillars. 2% BSA was perfused continuously at 0.2 ml/h through the 3D-μFCCS 
for 9 days. 2 ml perfusate was collected daily to quantify TGF-β1 concentration.  
 
6.2.4 Estimation of the concentration of controlled released TGF-β1 in the 
multi-channel 3D-μFCCS 
We aimed to control release 30 ng/ml of TGF-β1 in the multi-channel 3D-μFCCS. To 
obtain the final expected concentration of TGF-β1 in the centre cell culture 
compartment, we calculated the number of TGF-β1-loaded GMs needed in the 
multi-channel 3D-μFCCS. To estimate the number of GMs required to achieve a 
desired final concentration, the equation for calculation is used as previously 
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described,189 which is: 
( . 1) . . 3 3
.  
1 .
desired conc of TGF max No of GMs in D FCCS volume of D FCCS
No of GMs required
measured TGF conc volume of perfusate
β μ μ
β
   − ×     − ×  − =  
 − ×   
 
In the mucltichannel 3D-μFCCS, the number of GMs is ~10000; the volume of the 
cell culture compartment in the 3D-μFCCS is 0.06 μl; and the volume of the perfusate 
is 2 ml. 
 
6.2.5 Functional characterization of the cells 
Albumin secretion by C3A cells was measured according to the protocol provided in 
the Human Albumin Quantitative ELISA Kit (Bethyl Laboratories, USA). The PROD 
assay for A549 cells and GGT assay for HK-2 cells were performed as previously 
described192, 193 with modifications. The substrate concentrations used for the two 
assays were reduced to 1/3 of values previously described, and incubation with 
substrates was prolonged to 4 hours to improve the sensitivity of the assays. 
Adiponectin secretion by HPA was assayed according to the protocol provided in the 
Human Adiponetin ELISA Kit (Adipogen, Korea). Cell numbers were measured 
using PicoGreen Assay Kit (Molecular Probes, USA) according to the manufacturer’s 
protocol. The functions of the cells were normalized against the total cell numbers.  
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6.3 Results and discussion 
6.3.1 Development of a common, serum-free culture medium 
A variety of standard serum-free culture media have been previously optimized for 
each of the four cell types used.194-196 However, a mixture of these optimized standard 
media (OSM) does not necessarily maintain the functions of each of the four cell 
types when cultured in fluidically-linked compartments. In order to ensure that the 
cells maintain functional levels on par with, if not better than those cultured in their 
respective OSM, we developed a common medium (CM) incorporating the 
components of the OSM for each cell type. The basal medium of the CM was a 
mixture of all the basal media in different OSM. The growth factors and supplements 
used in each OSM were also incorporated in the CM at their appropriate 
concentrations (Table 1). The concentration of EGF, a common growth factor used in 
three of the standard media, was optimized for each cell type. We found that 50 ng/ml 
of EGF can efficiently maintain or enhance the functions of every cell type to be used 
(Fig. 26). The specific function measured for C3A cells is albumin secretion,197 for 
A549 cells is PROD enzyme activity,192 for HK-2 cells is GGT enzyme activity198 and 
for HPA cells is adiponectin secretion.199 The functional level for each cell type 
cultured in 2D monolayer with this CM was compared to that cultured with their 
respective OSM (Fig. 26, first two bars in each graph). Three of the four cell types 
maintained their specific functions in the CM on par with (C3A and HPA) or ~35% 
higher (A549) than in their respective OSM and only one cell type (HK-2) showed a 
~10% decrease in function. Thus we conclude that this CM is capable of sustaining 
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the functions of the four cell types on a level needed for subsequent experiments. 
 
Table 1: composition of the growth factors and supplements used in CM. The basal 
medium consists of MEM, DMEM/F12-K and RPMI 1640 in 1:1:1 ratio. 
 
Component Concentration 
Hepatocyte growth factor 30 ng/ml 
Oncostatin M 35 ng/ml 
Epidermal growth factor 50 ng/ml 
Insulin 0.5 μg/ml 
Transferrin 10 μg/ml 
Bovine serum albumin 1 mg/ml 
Hydrocortisone 50 nM 
Sodium selenite 25 nM 
Dexamethasone 400 ng/ml 
 
6.3.2 Effects of TGF-β1 on cellular functions 
Previous studies in our group showed that TGF-β1, a common growth factor found in 
the culture medium for a variety of cell types, promotes the functions of freshly 
isolated rat hepatocytes at its homeostasis level (100-200 pg/ml).189 However, other 
studies have reported different observation that TGF-β1 at a much higher 
concentration mediates the apoptosis of hepatoma cells via a series of signaling 
pathways.200 Therefore, at different concentrations, TGF-β1 will have different effects 
on various cell types. In this study, when investigating the effect of TGF-β1 on the 
four cell types, we discovered that at a much higher concentration than its 
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homeostasis level, it either stimulates or inhibits the function of each cell type to a 
different extent. At the concentration of 10-50 ng/ml, TGF-β1 efficiently stimulates 
the functions of A549 and HPA cells in 2D monolayer culture by ~1.5 fold. However, 
the function of C3A cells was severely inhibited by ~45% and the function of HK-2 
cells was also inhibited by ~15% (Fig. 27). Such differential effect presents the need 
to individually address TGF-β1 to A549 or HPA cells without compromising the 
functions of other cell types cultured in the multi-channel 3D-µFCCS. Since the 
cellular functions did not vary significantly with TGF-β1 concentration in the range of 
10-50 ng/ml (Fig. 27), we used TGF-β1 at a fixed concentration of 30ng/ml for 







Figure 26: optimization of EGF concentration in the CM. The functions of each of the four 
types of cells in monolayer culture under a range of EGF concentration were assessed by 
measuring (A) albumin secretion, (B) PROD activity, (C) GGT activity, and (D) adiponection 
secretion for C3A, A549, HK-2 and HPA, respectively. At 50-1000 ng/ml of EGF, the 
functions of C3A and A549 cells were stimulated by more than 3 fold, and that of HPA were 
slightly affected (slight inhibitory effect of ~10%). However, at above 50 ng/ml of EGF, the 
function of HK-2 cells dropped drastically by ~75% compared to the control. Therefore, a 
concentration of 50 ng/ml of EGF was used in the CM for optimized functions of all cell 








Figure 27: differential effects of TGF-β1 on cellular functions. The functions of each of the 
four types of cells in monolayer culture under a range of TGF-β1 concentration were assessed 
by measuring (A) albumin secretion, (B) PROD activity, (C) GGT activity, and (D) 
adiponection secretion for C3A, A549, HK-2 and HPA, respectively. At 10-50 ng/ml TGF-β1, 
the function of C3A cells were inhibited by ~45%, that of A549 and HPA were stimulated by 
~1.5 fold, and that of HK-2 were little affected (slight inhibitory effect of ~10%). Data are the 
mean ± s.e.m. of 2 independent experiments, **: p<0.05, *: p<0.1 
 
 
6.3.3 Perfusion culture of multiple cell types in the multi-channel 3D-µFCCS 
The multi-channel 3D-µFCCS contains four cell culture channels for the four 
different cell types, A549 (lung), C3A (liver), HK-2 (kidney) and HPA (fat) (Fig. 28A). 
The four channels are designed to be fluidically-linked. Each channel has an 
individual outlet used for functional analysis of each cell type (Fig. 28A). The 
micropillar array separates the central cell culture compartment from the two side 
perfusion channels (Fig. 28B). To investigate the biocompatibility of the 
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multi-channel 3D-µFCCS, we cultured the four cell types in a closed-loop perfusion 
manner (Fig. 28C). During cell culture, the outlet of the lung channel is kept closed so 
that medium can first perfuse through the lung channel and then through the other 
channels in parallel (Fig. 28C) similar to the human circulatory system.201, 202 
 
We investigated the viability of A549, C3A, HK-2 and HPA in the multi-channel 
3D-µFCCS after 48 hours, using 30 ng/ml of TGF-β1 as a supplement in the CM. 
A549, HK-2 and HPA were able to form viable multi-cellular aggregates even in the 
presence of TGF-β1 (Fig. 29). However, C3A showed a significantly decreased 
viability after 48 hours compared to other cell types, in agreement with their 
functional depletion in the presence of TGF-β1 in 2D cell culture (Fig. 29A). This 
observation led us to confirm that TGF-β1 cannot be simply supplemented in the CM 
to enhance A549 or HPA functions without affecting other cells cultured in the 
multi-channel 3D-µFCCS.  
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Figure 28: perfusion System set-up. (A) the schematic representation of the multi-channel 
3D-μFCCS, (B) the geometry of the 3D-μFCCS (the micropillar array separates the two side 
channels from the central channel) (C) the close-loop perfusion culture of cells. During 
culture, the A549 (lung) channel was closed to facilitate medium perfusion in a serial manner. 
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Figure 29: Evaluation of cell viability. In the presence of TGF-β1, (A) A549, (C) HK-2 and 
(D) HPA cultured in the multi-channel 3D-μFCCS after 2 days maintained high cell viability 
as shown in the confocal images upon staining with vital dyes, Calcein AM (green) for live 
cells and PI (red) for dead cells. (B) C3A cells showed a decreased viability (more red dots) 
compared to the others. Confocal images were maximum projections of 60-70 μm. 
 
6.3.4 Controlled-release of TGF-β1 from the GMs 
We have previously demonstrated controlled-release of TGF-β1 from GMs inside the 
3D-µFCCS189 and have confirmed that only limited amount of molecules could leak 
out to the side channels during perfusion (Fig. 20). Instead of perfusing TGF-β1 in the 
CM, we controlled-released it only in the A549 channel for demonstration. To 
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determine the number of GMs needed in the A549 channel, the controlled-release 
profile of TGF-β1 from the GMs was measured in the multi-channel 3D-µFCCS 
under the flow of 0.2 ml/h. When the A549 channel was fully packed with 
TGF-β1-loaded-GMs (~10000 GMs/channel), the average daily release was 340±92 
pg (Fig. 30). In order to deliver a daily concentration of 30 ng/ml of TGF-β1 in the 
multi-channel 3D-µFCCS, the amount of TGF-β1 needed was ~1.8 pg. Therefore, the 
number of GMs to be immobilized in the lung (A549) culture channel in order to 
release TGF-β1 at a concentration of 30 ng/ml was calculated to be ~50. 
 
 
Figure 30: characterization of the fabricated GMs. We measured the controlled release profile 
of TGF-β1 from the GMs in the multi-channel 3D-μFCCS under dynamic flow for 9 days. 
The GMs showed a linear release of TGF-β1. Data are the mean ± s.e.m. of 3 independent 
experiments. 
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6.3.5 Compartmental isolation between different cell types on the multi-channel 
3D-μFCCS 
To individually control the functions of different cell types, and thus imitate the in 
vivo situation that different organs are fluidically-linked by blood and yet relatively 
isolated from each other,187 we culture each cell type in separate microfluidic channels 
through which the CM was perfused. After 48 hours of culture in the multi-channel 
3D-μFCCS, the cellular functions of all the four cell types were measured (Fig. 31). 
When TGF-β1 was directly supplemented in the CM, the amount of albumin secretion 
from C3A drastically decreased by ~50% and the GGT enzyme activity of HK-2 
decreased by ~25%, compared to the control where no TGF-β1 was presented (Fig. 
31A, 31C). Meanwhile, the stimulatory effect of TGF-β1 on A549 and HPA was still 
observed, with a ~2.0 fold enhancement in PROD activity for A549 and a ~1.3 fold 
enhancement in adiponectin secretion for HPA (Fig. 31B, 31D). Therefore, this 
differential effect of TGF-β1 presented the need to individually address TGF-β1 to 
A549 cells. We controlled-released TGF-β1 from GMs only in the A549 channel to 
isolate its inhibitory effect on C3A and HK-2 cells. As expected, no inhibitory effect 
on the functions of C3A and HK-2 cells was observed, as indicated by their similar 
function levels as the controls (Fig. 31A and 31C); on the other hand, the stimulatory 
effect of TGF-β1 on A549 cells is still observed (Fig. 31B). For HPA cells, the 
function dropped to the same level as the control, mainly due to the fact that 
controlled-released TGF-β1 is localized in the A549 channel. Therefore, we confirmed 
that our controlled-release strategy can be utilized to achieve the compartmental 
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isolation needed in our multi-channel 3D-μFCCS.  
 
 
Figure 31: controlled stimulation of lung cell function on chip. 30 ng/ml of TGF-β1 was 
controlled-released from GMs in the A549 channel but not other channels on the chip, and the 
functions of (A) C3A, (B) A549, (C) HK-2 and (D) HPA were measured. 30 ng/ml of 
controlled-released TGF-β1 produces two-fold enhancement in A549 function, but has no 
effect on the functions of other cell types comparing to the control where no TGF-β1 was 
present (first and third bars). The functional levels observed by supplementing 30 ng/ml of 
TGF-β1 in the CM are shown for comparison (the bar in the middle) and the function of C3A 
cells was reduced. Data are the mean ± s.e.m. of 2 independent experiments, **: p<0.05, *: 
p<0.1 
 
In this study, we demonstrated the possibility of culturing different human cell types 
in a fluidically-linked fashion while maintaining their compartmental isolation from 
each other, so as to maintain or enhance their individual functions. The four cell types 
were chosen for our study because C3A and A549 exhibit liver- and lung-specific 
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functions and have the possibilities to be used for applications such as drug testing 
(C3A)155 and toxicity testing of nanoparticles (A549).156 HK-2 is a human kidney cell 
line that exhibits many of the specific functions found in human kidney, such as 
transporter activities and various enzyme activities involved in drug metabolism.198 
HPA is incorporated into the system because mature HPA resembles the adipose tissue 
that facilitates the storage of many lipophilic drugs.203, 204 This “reservoir” effect has 
to be taken into consideration when a systemic effect of a drug needs to be assessed.  
 
When the four cell types are cultured in the multi-channel 3D-μFCCS under the 
perfusion of the CM, their functional levels are heightened significantly compared to 
those cultured in 2D monolayers (Figs. 1 and 6). This suggests that culturing cells in 
3D is advantageous over that in 2D because higher cellular functions indicate higher 
sensitivities of the cells to external stimuli,176 and heightening the sensitivities of the 
in vitro cultured cells will help ensure that any drug tested by such a platform will be 
metabolized in a similar manner as in human. 
 
We also demonstrated the differential effect of TGF-β1 on the four cell types, which 
subsequently warrants the importance of compartmental isolation in the multi-channel 
3D-μFCCS. The micropillar array in our system confined the cells and biomolecules 
inside the central compartment, minimizing leakage into the side channels. We have 
observed that flow rates at a low level did not have any significant impact on the 
distribution pattern of the molecules inside the multi-channel 3D-μFCCS (Fig. 4C), 
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possibly due to the nature of laminar flow inside microfluidic devices.81 In principle, 
the laminar flow at the two side channels will not disrupt the environment in the 
central compartment while the mass transfer between the central and two side 
channels is diffusion-driven.  
 
The compartmental isolation not only mimics the in vivo situation of limited 
cross-talk between different organs, but is also applicable to culturing multiple cell 
types in general. Growth factors and other supplements required for one cell type very 
often affect the function of another cell type (as in the case of TGF-β1). Our strategy 
can successfully deliver a biochemical to the specific cell types without compromising 
the functions of others. This feature is of critical importance in applications such as 
drug toxicity testing or food safety screening, since any cytotoxic effect observed on a 
cell type should not be caused by interferences from other cells but only by the drug 




We developed a multi-channel 3D-μFCCS for culturing four different cell types to 
mimic four human organs: C3A (liver), A549 (lung), HK-2 (kidney) and HPA (fat). A 
common cell culture medium (CM) was optimized for enhancing the functions of all 
cell types. In addition to the CM, we found that TGF-β1 can enhance the functions of 
A549 and HPA but inhibit the functions of C3A. Thus, we specifically 
controlled-released TGF-β1 from GMs inside the A549 channel during cell culture. As 
a result, the function of A549 was enhanced while the functions of C3A and HK-2 
were uncompromised, demonstrating compartmental isolation between different cell 
types similar to the in vivo situation. Such a cell culture method can be used to 
simultaneously culture multiple cell types and control their cellular functions 
individually for various applications such as drug testing or food safety screening. 
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CHAPTER 7 Conclusion 
This thesis documented the process of engineering a soluble microenvironment in 
microfluidic systems. The process consisted of system validation of the 3D-µFCCS, 
optimization of the GM fabrication, characterization of the GMs and evaluation of the 
incorporation of GMs into the 3D-µFCCS. We optimized the design of the previously 
designed 3D-µFCCS for more constant fluid flow and minimized bubble formation. 
The versatility of the 3D-µFCCS was further validated by culturing various cell types 
originated from different species and organs. Meanwhile, the conditions for GM 
fabrication were optimized by evaluation of GM morphology as well as measurement 
of their controlled-release properties. The GMs can be immobilized together with 
cells in the 3D-µFCCS, given proper GM/cell ratios. They were also able to 
controlled-release molecules with different molecular weight. The soluble 
microenvironment composed of the molecules released from GMs in the 3D-µFCCS 
was characterized under fluid flow. Results indicated that a relative constant soluble 
microenvironment was localized in the central cell culture compartment, regardless of 
the fluid flow rate. Therefore, we conclude that controlled-release of molecules from 
GMs can facilitate the creation of a constant soluble microenvironment in the 
3D-µFCCS. 
 
Based on the engineered soluble microenvironment, we demonstrated two different 
applications in microfluidic systems. In Chapter 5, we created a soluble 
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microenvironment to replace hepatocyte-fibroblast co-cultures for maintaining 
hepatocyte functions in vitro. This was achieved by creating the soluble 
microenvironment composed of TGF-β1. 200-220 pg/ml of controlled-released 
TGF-β1 resulted in higher hepatocyte functions compared to directly-perfused 
TGF-β1 or the control without TGF-β1. The measured hepatocyte sensitivity to APAP 
induced cytotoxicity in our 3D-μFCCS with in situ controlled-released TGF-β1 
approaches that of the in vivo drug-induced hepatotoxicity. 
 
Another application of culturing multiple cell types was demonstrated in Chapter 6. A 
multi-channel 3D-μFCCS was developed for culturing four different cell types to 
mimic four human organs: C3A (liver), A549 (lung), HK-2 (kidney) and HPA (fat). 
We found that TGF-β1 can enhance the functions of A549 and HPA but inhibit the 
functions of C3A. Therefore, TGF-β1 was specifically controlled-released inside the 
A549 channel during cell culture. The function of A549 was found to be enhanced 
while the functions of C3A, HK-2 and HPA cells were uncompromised, 
demonstrating compartmental isolation between different cell types similar to the in 
vivo situation.  
 
The strategy of engineering soluble microenvironments in microfluidic systems 
significantly enhanced the biological functions of either primary cells or cell lines. 
This strategy sees various cell-based applications such as hepatotoxicity testing, the 
testing of the systemic effects of a drug, or food safety monitoring. 
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CHAPTER 8 Recommendations for Future Research 
8.1 Biological validation of cells cultured in the 3D-µFCCS with the engineered 
soluble microenvironment  
Evaluations on the gene expression profiles,205 the expression of specific markers206 
and the localization of structural proteins36 have indicated that cells cultured in 3D can 
approach in vivo situations, compared to those cultured in 2D monolayer. Therefore, it 
has been widely accepted that cells cultured in 3D can reflect their in vivo situations 
better than those cultured in 2D.207 In this thesis, based on 3D cell culture, we have 
successfully engineered the soluble microenvironment in the 3D-µFCCS by 
establishing cell-soluble factor interactions, which allows for the development of in 
vitro models for cell-based applications. Therefore, it is necessary to perform detailed 
characterization of the phenotype and genotype to validate that cells cultured in our 
system are indeed more physiologically relevant than other 2D or 3D microfluidic 
systems. 
 
The assays for characterization are highly dependant on the applications of the system. 
For instance, primary hepatocytes and other liver-derived cell lines are good models 
for in vitro drug-testing. The focus of the characterization should be on the 
drug-metabolism activities of the cells e.g. secretion functions, enzymatic activities, 
transporter activities, and excretion functions. Also, if the soluble microenvironments 
are used for studying stem cell behaviors, the specific markers, e.g. alkaline 
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phosphatase activity of osteoblasts208 and Notch for embryonic stem cells,209, 210 
should be well-characterized. Many commercially available microarrays such as 





8.2 Development of an integrated system for physiologically based 
pharmacokinetic (PBPK) studies 
We have demonstrated the engineering of a constant soluble microenvironment in 
section 4.3.7 and also in Chapter 6 the capability of the multi-channel 3D-µFCCS to 
culture multiple cell types. The multi-channel 3D-µFCCS can further be used as a cell 
culture platform for PBPK studies, where the systemic effect as well as the 
pharmacokinetics of the drug can be evaluated. To engineer a physiologically based in 
vitro system to mimic the physiology of a human for pharmacokinetic studies, the 
design of the multi-channel 3D-µFCCS has to be modified according to physiological 
data (Appendix II).211 Since the weight of the organs varies, the sizes of the cell 
culture compartments have to be different. The ratio of flow distribution and residence 
time in different cell culture compartments has to be the same as that in human body. 
Therefore, resistances need to be incorporated after each cell culture compartment to 
ensure proper flow distribution on chip (Fig. 32 and Appendix II).  
 
Figure 32: the multi-channel 3D-µFCCS designed according to human physiology. The ratios 
between the size of lung, liver, kidney and fat chambers are in accordance with that found in 
vivo. The dummy chamber is meant for flow distribution. Different resistances with varied 
lengths are incorporated in each cell culture chamber to achieve different amount of blood 




The cells have to be cultured under a close-loop medium perfusion in the 
multi-channel 3D-µFCCS to mimic blood circulation in vivo. However, in Chapter 6, 
the volume of medium being circulated in the system is huge compared to the weight 
of the cells. This could lead to diluted concentrations of drugs and their metabolites, 
creating difficulties for sample measurement. The usage of medium can be greatly 
reduced if circulation can be achieved on chip. Pneumatic PDMS valves can be 
incorporated for the continuous opening and closing of the channels212, 213 and thus the 
pumping of medium in the multi-channel 3D-µFCCS. The valves are made from a 
very thin layer of PDMS so that they have excellent deformability. The valve layer is 
exactly aligned with the channel layer (Fig. 33) and is connected to a gas tank which 
generates pressure. Therefore, when the valves deform under pressure, they can 
effectively block the channels. When the pressure is removed, liquid can flow through 
the channels again (Fig. 34).  
 
Figure 33: schematic representation of the pneumatic valves in the multi-channel 3D-µFCCS. 
It is a two-layered system. The green layer indicates the four channels meant for perfusion 
cell culture. The red layer indicates the pneumatic PDMS valves which are meant for 










Figure 34: the working principle of the pneumatic valves. A) side view of the PDMS valves. 
The thick grey and red layer is the PDMS chip with the features of the microfluidic channel. 
Blue indicates the thin PDMS layer with the features of the valve. B) When the hollow valves 
are filled with air, they will hump up and block the microfluidic channel on top.
 131
8.3 Development of a platform for monitoring the effects of a microenvironment 
on stem cells
The key focus on stem cell research is to maintain them in vitro and to coax them to 
differentiation into desired cellular phenotypes.117 Stem cells exist within the complex 
microenvironment, where extensive cell-cell, cell-matrix and cell-soluble factor 
interactions are found.19 However, there is still not enough knowledge on the stem cell 
microenvironment which regulates their self-renewal and differentiation.214, 215 This 
deficiency of understanding is possibly due to the complexity of the soluble factors in 
the microenvironment, the lack of available tools for observation113 and the lack to 
technology to engineer a microenvironment. 
 
Our 3D-µFCCS is transparent and allows for imaging and analysis of cellular 
behaviors. With the engineered soluble microenvironment in the 3D-µFCCS, we can 
load different molecules onto GMs and hence observe the impact of different 
combinations of soluble factors on cells. By varying the number of GMs in the cell 
culture compartment, the concentration gradient of the released molecules and hence 
cellular behaviors can be manipulated. The output of the device can be analyzed for 
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APPENDIX I Important Protocols 




z 1L bottles (x3) - autoclaved 
z Sterile glass rod (x1) – autoclaved 
z Magnetic stirrer (x2) – soaked in 70% ethanol 
1. Prepare methanol + 0.1 M HCl: pour 1L of methanol into a sterile 1L bottle inside 
a fume hood and add 8.35 µl of 37% HCl. 
2. Pour 1L of acetone into sterile 1L bottle (x2) 
3. Transfer all items into laminar flow hood. 
4. Precipitate collagen by pouring 50ml of collagen I solution (Vitrogen 1000) into 
1L of acetone. Swirl bottle slightly. 
5. Pour excess acetone into a clean bottle and use sterile glass rod to squeeze out 
remaining acetone from precipitated collagen. Dry inside the hood for 5-10 min to 
allow acetone to evaporate. Remove as much acetone as possible. 
6. Pour 500 ml of methanol + 0.1 M HCl into each bottle containing precipitated 
collagen. 
7. Transfer into 4°C cold room and stir (at low speed) for 6 days. 
 
Preparation of dialysis tubings 
1. Cut dialysis tubing into length of 32cm (x33) 
2. Soak in DI water for 1-2 days; run DI water through the tubings for approximately 
half a day. 
3. Transfer dialysis tubings into a 1L sterile bottle and sterilize with 70% ethanol for 
30 min-1 hr (max). 




z 4L Nalgene containers filled with DI water (x11; 2 containers with red labels 
should contain magnetic stirrer as well) - autoclaved. 
z 2L beakers (x2) – autoclaved 
z Funnel (x1) – autoclaved 
z Freeze drying bottles (x3) – autoclaved 
z Freeze drying bottle tops (x3) – soaked in 70% ethanol 
z Filters for freeze drying bottles (x3) – autoclaved 
 
1. Rinse dialysis tubings with 1 container of sterile DI water and transfer tubings into 
1 sterile beaker. 
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2. Tie one end of the dialysis tubing and fill it up with methanol-collagen solution 
using the sterile funnel. Tie the other end of the dialysis tubing to secure it. 
3. Place filled dialysis tubing into 1 4L container with sterile DI water (red label with 
stirrer). 
4. Repeat step 2-3 until all methanol-collagen solutions are transferred into dialysis 
tubings. 
5. Place container into 4°C cold room. 
6. Complete 4 changes of water with remaining 8 containers of DI water with the 
next 24 hours. Check the PH of the water (~7 after 4 changes of water). 
7. Pour away excess water into waste bottle. Transfer all the dialysis tubings into a 
sterile beaker. 
8. Untie dialysis tubing and transfer collagen solution into sterile 50 ml tubes. 
9. Freeze collagen solution at -30°C. 
10. Freeze dry collagen. 
11. Collect dried collagen from 50 ml tubings and pool collagen modified from an 
initial volume of 50 ml collagen. Weigh collagen and indicate on the weight on the 
tubings. Note: when preparing collagen solution, DO NOT weighs small 
quantities of collagen as it increases weighing errors. 
 
B. Procedures for seeding cells in 3D-µFCCS 
 
Table 2: parameters for cell seeding in 3D-µFCCS 
 SINGLE CHANNEL 4-CHANNEL 
Cell 
immobilization
• hepatocytes density = 1-2x106 
cells/ml 
• Withdrawal flow rate = 0.02 – 
0.04 ml/hr 
• cell line density (cell lines)= 
9-10x106 cells/ml 
• Total withdrawal flow rate 










































Perfusion flow rate = 0.05-0.07 
ml/hr  
Perfusion flow rate = 0.15-0.25 
ml/hr  
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APPENDIX II the Design of the Multi-Channel 3D-µFCCS According to 
Human Physiology 
 
Table 3: physiological data for human 
Body weight (kg) 70 
Cardiac output (CO) (L/hr) 347.9 











Calculation of resistances 
Cell lines are used to construct the artificial organs in the four-channel system. The 
difference of their size and density is negligible. Thus, provided the constant width of 
the channels, the ratio of cell mass in each channel is the same as that of the channel 
length. Ro is incorporated into the system as a resistance to facilitate blood 
distribution. When the channels are fully packed with cells, the final resistances of the 
channels should be reversely proportional to their flow distribution (Table 1). 
 
 
Rlu: resistance of the lung channel 
Rli: resistance of the liver channel 
Rk: resistance of the kidney channel 
Rf: resistance of the fat channel 
Ro: resistance of the other organ 
channel 
Rli= Rk, Rf= 5 Rk, Ro= 5/9 Rk
Flow distribution through lung is 
100% 
Figure 35: flow distribution resistances 
 
However, each channel has an intrinsic resistance due to the ratio of the organs. Thus, 
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by incorporating additional resistances to specific channels, the final resistances can 
be obtained to mimic flow distribution. The calculation process is shown in Fig. 36. 
 
 Resistance value of channel, with cells and flow distribution 
 Rli =3.14/0.44Rk = 7.1 Rk; Rli = Rk
 Rf = 3.465/.044Rk = 7.9 Rk; Rf = 5 Rk
 Ro =5/9 Rk




Rk = Rk + 6.1 Rk
Rli = 7.1 Rk
Rf = 7.9 Rk + 27.6 Rk
Ro = 3.9 Rk
Rl = 2.61 Rk
 
Figure 36: total resistances (Red highlights indicate the value of the additional resistances) 
 
To ensure enough cells for biological characterization, the lower limit of cell number 
in the microfluidic channel is 5000. The size of a cell is around 10 µm (By empirical 
observation). Thus, the volume of a cell is no more than 1000µm3 
(10µm×10µm×10µm). Based on this assumption, and provided that the width of the 
channels is consistent (200µm+200µm+200µm), the length of the channels can be 
calculated: 
Liver: 1 cm 
Kidney: 0.14 cm 
Fat: 1.1 cm 
Lung: 0.36 cm 
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APPENDIX III Imaging-Based Assay for Quantifying the Viability of 
Hepatocytes 
 
Figure 37: confocal images of staining for necrotic and total cell population in the 3D-µFCCS 
after 24 hours of treatment with 40 mM APAP (A) The necrotic cell population was stained 
with 25 μg/ml PI and (B) the total cell population was stained with 5μg/ml Hoechst 33342. (C) 
Overlay of red and blue channels where blue indicates total cells and co-stained red nuclei 
indicate necrotic cells. Images are projection of a 100 μm optical stack at 2 μm interval. Scale 
bars = 50 μm.  
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